Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors

Liangliang Xu1†, Chang Zou2,3,4†, Shanshan Zhang5†, Timothy Shun Man Chu6,7, Yan Zhang1, Weiwei Chen8, Caining Zhao6, Li Yang1, Zhiyuan Xu1, Shaowei Dong2, Hao Yu10, Bo Li11, Xinyuan Guan1,8,9*, Yuzhu Hou12* and Feng‑Ming Kong1,8*

Abstract

The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must involve the systemic tumor immune environment (STIE) which was merely illustrated previously. Here, we aim to review recent advances in single-cell transcriptomics and spatial transcriptomics for the studies of STIE, TIME, and their interactions, which may reveal heterogeneity in immunotherapy responses as well as the dynamic changes essential for the treatment effect. We review the evidence from preclinical and clinical studies related to TIME, STIE, and their significance on overall survival, through different immunomodulatory pathways, such as metabolic and neuro-immunological pathways. We also evaluate the significance of the STIE, TIME, and their interactions as well as changes after local radiotherapy and systemic immunotherapy or combined immunotherapy. We focus our review on the evidence of lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, aiming to reshape STIE and TIME to enhance immunotherapy efficacy.

Keywords: Tumor immune microenvironment (TIME), Systemic tumor immune environment (STIE), Immunotherapy, Radiotherapy, Single-cell transcriptomics
adoptive cell therapy, antibody−drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs). Among them, ICIs by using antibodies to programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are the main and most successful immunotherapy candidates thus far [1, 2]. PD-1 is induced on T cells following TCR signaling activation and leads to impaired T cell function and to immune escape upon ligation to its ligand PD-L1. PD-1 inhibitor immunotherapy blocks the interaction between PD-L1 on the surface of tumor cells or antigen-presenting cells and PD-1 on the surface of CD8+ T cells. It reactivates the tumor-killing ability of CD8+ T cells, thereby exerting anti-tumor effects. The PD-L1 and PD-L2 are the two ligands for PD-1. The PD-L1 inhibitor only blocks the binding of PD-1/PD-L1, while PD-1 inhibitor blocks the bindings of both PD-1/PD-L1 and PD-1/PD-L2 at the same time [3]. Meanwhile, PD-L1 can also bind to other receptors like B7-1 (CD80) [4]. Inhibition of PD-1/PD-L1 binding reactivates the tumor-killing ability of CD8+ T cells, thereby exerts anti-tumor effects. Although some reported that PD-1 inhibitors may have better efficacy than PD-L1 inhibitors and a higher incidence of pneumonitis that PD-L1 inhibitors [5], there is no strong evidence showing the superiority of one over the other. We thus elect PD-1 inhibitor as representative of immunotherapy for the following review.

Currently in the clinic, the use of the biomarker-guided PD-1 inhibitor immunotherapy is mainly guided by the PD-1/PD-L1 expression level, tumor mutation burden (TMB), and tumor microsatellite instability (MSI) [6, 7]. In advanced non-small cell lung cancer (NSCLC), PD-1 inhibitor immunotherapy increased the 5-year survival rate from less than 5% to around 16% [8, 9]. For stage IV NSCLC patients with PD-L1 expression ≥ 50%, the 5-year survival rate reached 31.9% [8, 9]. In advanced hepatocellular carcinoma (HCC) without knowledge of PD-L1 expression levels, the median survival time of patients was less than 1 year, and the median survival time with PD-1 inhibitor immunotherapy alone reached 15.6 months [10, 11]. Among Chinese patients administered with PD-L1 inhibitors combined with VEGF inhibitors, the median survival time was up to 24.0 months [12, 13]. In advanced nasopharyngeal carcinoma (NPC), the progression-free survival (PFS) of PD-1 inhibitor immunotherapy alone was 4.7 months and the 6-month PFS rate was 50% [14], while PD-1 inhibitors combined with chemotherapy achieved an objective effective rate of up to 91%, a disease control rate as high as 100%, and an 86% 6-month PFS [15]. Overall, there are significant successes in clinical practice in immune checkpoint inhibitors in many other solid tumors in addition to the above-mentioned cancers [16–18]. Tumor immunotherapy strategies based on immune checkpoint inhibitors and immune cell therapy have become the frontier of oncology research. However, the overall pan-cancer response rate of PD-1 inhibitor alone was only 20% [19], while combination with radiotherapy increased the response rate to 40% [19]. The underlying reasons for such a low response rate are poorly understood.

In the past, tumor immunology research mainly studied the genomic/transcriptomic profile at the cell population level or detected the expression of a few molecules in tumor tissue. However, these strategies cannot fully describe the functions of various cell types or characterize the changes involved in the immune processes of malignant tumors, largely due to the high heterogeneity, complexity, and plasticity of the tumor immune microenvironment (TIME).

One must be kept in mind that cancer progression and their responses to treatment are also directly influenced by systemic tumor immune environment (STIE), i.e., the global immunity of the host, the macro-environment of the host anti-tumor immunity. STIE, in coordination with TIME, determines the host responses to the immunotherapy. Hiam-Galvez et al. [20] (recently published in Nature Review Cancer) described such systemic cancer immunity focusing on the immune cell traffic in the STIE, connecting the STIE with lymphatic organs, largely based on the data from the mouse models. This review aims to illustrate the orchestrated effect of the TIME and STIE, through the use of the modern technologies such as the single-cell technology and spatial transcriptomics, in the context of patient and tumor as a whole, with an emphasis on the major challenges facing cancer immunotherapy. Additionally, it further assesses the immune modulating effects of cancer local radiotherapy on systemic therapy, to explore strategies to reshape TIME and STIE for improved efficacy of tumor immunotherapy.

The tumor microenvironment (TIME), tumor immune microenvironment (TIME), and systemic tumor immune environment (STIE)

Solid tumor is a highly complex tissue containing highly heterogeneous cancer cells that differ in compositions and evolutionary states derived from different upstream mutations and the tumor microenvironment (TME) formed by immune cells, stromal cells, blood/lymphatic vessels, nerve terminals, and extracellular matrix (ECM) which contains various signal molecules and acts as immune modulating microenvironment that continuously reshapes the local immunity. The composition of TME is a key determinant of tumor–host interaction. Tumor immune microenvironment (TIME), composing different cell groups of the immune system and their interactions in the TME niche, has been known for its key role on the processes of carcinogenesis, cancer
progression, and responses to the treatments [21]. TIME can be divided into infiltrated–excluded (“Cold tumors”) in which CD8+ T cells were excluded from the tumor center, and infiltrated–inflamed (“Hot tumors”) in which an infiltrated–inflamed TIME was observed, as demonstrated by the increased expression of PD-L1 in tumors and highly activated CD8+ T cells expressing GRZB, IFN-\(\gamma\), as well as the presence of infiltrated–tertiary lymphoid structures (TLSs) that are like lymph nodes, containing B cells, dendritic cells, and Treg cells [21]. “Hot tumors” have more specific molecular markers on the surface that can be recognized and attacked by T cells that can trigger the anti-tumor immune responses. PD-1/PD-L1 inhibitors increase the interaction between conventional dendritic cells (cDCs) and naive T cells in the draining lymph node and co-stimulated with CD28, facilitating the initiation and rapid expansion of new T cell clones with new antigen specificities [22, 23]. Moreover, PD-1/PD-L1 inhibitors also prompt the reproduction of existing T cell clones in circulation. These expanding peripheral T cells eventually infiltrate the tumor in the TIME and express markers of antigen-specific activation and display functional cytotoxicity [20–23]. In addition, CD40 agonism can be used to accomplish productive de novo immune responses. It can actuate cDC activation in the presence of resistance to checkpoint blockade and trigger these new T cell responses to replace exhausted intratumoral clones [20, 21]. Cancer cells with inclusion of a small proportion of cancer stem cell (CSC) interact with TIME immune cells (e.g., macrophages, MDSCs; DCs; NK cells; T cells; B cells), stromal cells (e.g., fibroblasts and cancer-associated fibroblasts) and the ECM within TME and result in immune activation or immunosuppression effects, thereby affecting the proliferation or metastasis of tumor cells [24].

STIE, primarily controlled by the circulating blood and lymphatic vessels, consisting of the immune modulating molecules and immune cells (Fig. 1), plays an imperative

---

**Fig. 1** STIE and TIME relationship. The anatomic and interactive relationship between TIME and STIE as well as key components of STIE are shown. STIE circulating in the blood and lymphatic vessels are in close contact with, and directly provide cell and molecular components to the tumor extracellular matrix which can be considered as part of TIME. The major cell and immune regulator components of STIE and TIME may vary with cancer type, examples of non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and nasopharyngeal carcinoma (NPC) are summarized in Table 1. CC, cancer cell; CSC, cancer stem cell; Mac, Macrophage; DC, Dendritic cell; MDSC, myeloid-derived suppressor cells; NK, natural killer cells; IDO, Indoleamine 2,3-dioxygenase; Kyn, kynurenine; Trp, tryptophan.
role in communication between the primary tumor site to the distant organs and the host immune organs such as bone marrow and lymph nodes [20]. The functional immune modulators include proteins, cytokines, and metabolites, while the immune cells comprise myeloid cell lineages (neutrophils, monocytes, megakaryocytes, platelets, basophils, eosinophils) and lymphoid cell lineages (T cells, B cells/plasma cells, and NK cells).

There are extensive interactions between TIME and STIE. STIE and TIME are closely related to each other and integrated through capillary vessels and lymphatic drainage system in the tumor. The circulation of lymphatic vessels and blood vessels, which carry immune modulating factors and immune functional cells, is the direct link between the TIME and STIE. Tumors can invade through the blood or lymphatic vessels with the help of immune cells from STIE, and after the infiltration of tumor into the blood or lymphatic vessels, immune cells within the STIE entered the TIME and promoted the metastasis of tumor cells. For example, monocytes derived from the peripheral blood (STIE) could enter the tumor tissue and differentiate into macrophages [25]. Preclinical data from various human and mouse cancer models showed that cancers disrupted the hematopoiesis which subsequently restricted the expansion of immature neutrophils and monocytes in the STIE. Then, this cripple STIE hinders the transport of immune cells to TIME sites which contribute to local immunosuppression [20]. In addition to the commonly studied cellular components of TIME (Fig. 1), immune modulating molecules like TGF-β1, IDO, and Artemin in the ECM have also been considered as important parts of STIE in local tumor, and to play critical roles in cancer development and cancer immunity [26–28]. Many cell components of the TIME are up- or down-regulated (comparison with adjacent normal tissue), while many of the cell components and immune regulators in STIE can be higher or lower than that of the primary tumor, or non-cancer donors. Similarities and variations are also observed from one primary tumor to another, as examples in NSCLC, HCC, and NPC (Table 1). In general, the exhausted T cells increased in the TIME and STIE of tumor patients.

The compositions of STIE and TIME are very complex and involve various pathways and mechanisms and vary with the primary tumor types [29–32, 41–51, 56–60] (Fig. 1 and Table 1). Majority of cell and molecular components in the TIME are also present in STIE, at a level similar, higher, or lower relative to TIME. One has to note that the research on cellular molecular level of the STIE is very limited at this time, in particular comparison with the TIME.

The efficacy of immunotherapy relies heavily on the status of STIE and TIME. Immunotherapy augments the anti-tumor immunity in the STIE and TIME and becomes a new strategy for tumor treatment that has brought fundamental changes in the fields of cancer research and cancer care. To summarize the interactive roles of STIE and TIME and clarify their impacts on tumor progression.

### Table 1 Major immune components of STIE and TIME

| Cancer type | STIE Cell | Immune regulator | TIME Cell | Immune regulator | REF |
|-------------|-----------|------------------|-----------|------------------|-----|
| NSCLC       | ↑: CD8⁺, GranB⁺↑, Naive CD4⁺, CD4⁺NK, Ter cell, NK, Cytolytic CD16⁺NK, CD14⁺ monocyte, basophil ↓: CD8⁺PD-1⁺↑, CD8⁺T CM, Treg, CD1c⁺DC, Macrophage, Eosinophil, Mast cell | ↑: TGF-β1, IDO, Artemin, PD-1, PD-L1, CTLA-4, GITR, IL-17 ↓: BMI1 | ↑: CD8⁺PD-1⁺↑, CD8⁺T CM, Treg, Infiltrated CXCR3⁺NK, CD1c⁺CD -: Naive CD4⁺, Macrophage, CD14⁺monocyte, Neutrophil, Eosinophil ↓: CD8⁺ GranB⁺↑, CD16⁺monocyte, NK, CD4⁺NKT, Cytolytic CD16⁺NK, Basophil, Mast cell | ↑: TGF-β1, CTLA4, CD11c, CD14, CD39, ICOS, 41BB, IL-6, PPARy ↓: IL-8, IL-1β, IFN-γ, Granzyme B, CD57, CD86, CD206 | [29–40] [29*] |
| HCC         | ↑: Treg, MDSC ↓: CD8⁺↑, CD4⁺↑ | ↑: PD-1, IL-6, LAYN ↓: PD-1, CTLA4, IFN-γ, LAG3, TIM3, PTPRO | ↑: CD8⁺↑, Treg, B cell, Monocyte, DC, Kupffer cell, Neutrophil ↓: NK, NKT | ↑: PD-1, PD-L1, CTLA4, TIM3, LAG3, IFN-γ, IL-10, IgA ↓: CCL4, CCL14 | [41–55] |
| NPC         | ↑: NK, PD-1⁺↑, NK ↓: Treg ↑: CD8⁺↑, CD4⁺↑, B cell ↓: IL-2, IL-10, IL-18, MMP-9, CR1, IgM | ↑: CD8⁺↑, Treg, B cell, PD-1⁺CXCR5⁻CD4⁺Th CXCL13, CD19⁺B cell ↓: NK | ↑: CD8⁺↑, Treg, B cell, PD-1⁺CXCR5⁻CD4⁺Th CXCL13, CD19⁺B cell ↓: NK | ↑: CD1, FOXP3, LAG3, HAVCR2, IFN-γ, IL2RA, IL-18, IL-21, CCL19, CCL20, CXCL10, CXCL13 | [56–65] |

†: Upregulation; ↓: Downregulation; -: No significant change in the cited literature studies; ↑: up-regulated; ↓: down-regulated. Some escalate compared with normal tissue or non-cancer donors; *: Compared with tumor tissue; T T cells, TCM central memory T cell, NK natural killer, NK T natural killer T cell, DC dendritic cell, REF reference. NSCLC non-small cell lung cancer, HCC hepatocellular carcinoma, and NPC nasopharyngeal cancer are shown as examples.
and therapeutic efficacy, we elected to address the following challenges associated with PD-1 inhibitor treatment: (1) an overall low response rate and the heterogeneity of therapeutic efficacy of immunotherapy, (2) the communications between STIE and TIME that establish the environment for cancer metastasis (e.g., brain metastasis), (3) hyperprogressive disease, and (4) treatment-related adverse effects. Additionally, we will take snapshot of the accumulating evidence of the changes of TIME and STIE induced by local radiation therapy (RT) and systemic ICI therapy, to explore the reshaping strategies which may provide strategies to improve the efficacy of immunotherapy by modulating TIME and STIE.

**STIE and TIME on the heterogeneity of immunotherapy efficacy**

**STIE on immunotherapy efficacy**

The significant impact of STIE on the cancer immunotherapy efficacy was recently comprehensively emphasized by a study from Stanford by Spitzer, demonstrating the key role of STIE on cancer immunotherapy [20]. The investigators performed an organism-wide study in genetically engineered cancer models using mass cytometry and analyzed immune responses in several tissues after immunotherapy and developed intuitive models to visualize single-cell omics data with statistical inference. They reported that: (1) systemic immune activation was evident shortly after effective therapy was administered; (2) during tumor rejection/eradication, only systemic peripheral immune cells sustained their proliferation, (3) an emergent population of peripheral CD4+ T cells were significantly expanded in patients responding to immunotherapy. This work emphasized the critical impact of systemic immune responses that drives tumor regression. Recently, a comprehensive review summarized responses of STIE immune cells to ICI treatment [20] demonstrated the critical role of systemic immunity (equivalent to our STIE) for effective natural and therapeutically induced anti-tumor immune responses, with most of the literature from studies of mouse models. In clinic, reduction in circulating lymphocytes, i.e., lymphopenia, an important change in cell component of STIE, has been widely observed and recognized to impact the tumor control and the therapeutic efficacy of various cancers such as lung cancer, breast cancer, pancreatic cancer, melanoma, and sarcoma [66]. In addition, it has been reported that high levels of lymphocytes and low neutrophil-to-lymphocyte ratio (NLR) are associated with better survival of lung cancer patients [67]. In patients with liver cancer receiving immunotherapy, it was noted that those who did not respond to immunotherapy had higher CD4+ T cells and Th17 cells and lower CD8+ T cells [68]. Viral carcinogenesis-associated HCC and NPC are mainly caused by chronic hepatitis B virus (HBV) and Epstein–Barr virus (EBV), respectively. NPC, an endemic disease usually found in Southeast Asia and North Africa and etiologically linked to Epstein–Barr virus infection, represents a classic "inflammatory tumor" that exhibits dense lymphocytes infiltration and high expression of PD-L1 [69]. Stromal cells are in close proximity to and in contact with NPC cells, which could make NPC microenvironment highly heterogeneous and immunosuppressive, preventing tumor cells from being infiltrated by drugs and immune attack, and promote tumor progression. Therefore, the NPC is a heavily immune cell infiltrated cancer with a low degree of differentiation. The high infiltration status of macrophage, plasmacytoid DC (pDC), DC1, NK cell and plasma cells were associated with good prognosis of NPC. There is a dynamic status of T cells from activation to exhaustion in TIME in patients with NPC. The exhausted T cells exhibit features associated with tertiary lymphoid structures (TLS) formation via B cell recruitment and increased abundance of suppressive regulatory T cell (Treg) in the microenvironment, where myeloid recruitment is an NPC-specific event. In addition, T cells entered the TIME and upregulated the activity of IFN-α and IFN-γ response pathways in macrophages, suggesting a potential anti-tumor capacity of these macrophages in NPC [56, 69, 70]. In summary, the composition of TIME explained the mechanism of PD-1 inhibitor immunotherapy efficacy.

**PD-L1 in STIE on immunotherapy efficacy**

The circulating immune regulatory factors of the STIE have also been studied as biomarkers in predicting the treatment outcome in clinic. Such effect has been frequently demonstrated in clinical studies. For example, the expression status of PD-1/PD-L1, TGF-β1, and IDO1 was different among individuals even with the same type of cancer. A study of 107 patients with NSCLC revealed that PD-L1 has an observed intratumoral heterogeneity in 78% and inter-tumor heterogeneity in 53% of cases [71]. Plasma soluble PD-L1 (sPD-L1) is another key STIE factor which is elevated in a variety of malignancies and has clinical significance [33]. Okuma et al. [33] reported that majority (75%) of patients with high plasma sPD-L1 levels experienced disease progression in NSCLC treated with the PD-1 inhibitor nivolumab. The time to treatment failure and overall survival (OS) were significantly worse in those with higher plasma sPD-L1 levels when compared to those with lower levels. Similarly, Mazzaschi et al. found that high levels of sPD-L1 negatively affected progression-free survival (PFS) and OS in 109 NSCLC patients treated with ICI [72]. Finkelmeier et al. [73] also found that plasma sPD-L1 levels were positively correlated with liver cirrhosis and cancer stage related
in HCC patients who were exposed to PD-1 inhibitor immunotherapy. Indeed, our recent meta-analysis of 8 studies (710 patients) demonstrated that plasma sPD-L1 levels were associated with the clinical outcome of tumor patients and might serve as a predicting biomarker of OS in NSCLC patients given with ICI-based therapies [74].

**TGF-β1 in STIE on TIME and tumor response to PD-1 inhibitor immunotherapy and radiotherapy**

TGF-β1 is a known immune suppressor which plays a key role in immune modulation. Figure 2 shows the multiple roles of TGF-β1 on TIME and STIE. TGF-β1 has dual roles in the TIME and STIE. TGF-β1 has multiple impacts on different kinds of immune cells. The detail functions of TGF-β1 are shown by different arrows (Solid arrow: stimulation, Dashed arrow: possible stimulation, Vertical-horizontal line: suppression). TGF-β1: Transforming growth factor-beta1, TIME: Tumor Immune Microenvironment, STIE: Systemic Tumor Immune Environment.
patients had an increased level of TGF-β1 [34], which decreases sharply after radiotherapy [81]. TGF-β1 may be used to predict the long-term outcome of lung cancer patients receiving radiotherapy. Monitoring TGF-β1 level may help predict the persistence and recurrence of the disease after treatment [82]. Meanwhile, we also have demonstrated and validated in patients with NSCLC that the addition of IL-8 and TGF-β1 improved model accuracy for radiation-induced pulmonary toxicity (RILT) [83, 84]. In addition, in 166 inoperable stage I–III NSCLC patients who received chest radiotherapy (≥55 Gy) with or without chemotherapy, 14 functionalities of 11 genes in the TGF-β1 pathway were detected via genetic variations of single-nucleotide polymorphisms (SNPs). Four SNPs (SMAD3: rs12102171, BMP2: rs235756, SMAD9: rs7336607, and SMAD4: rs12456284) were found to be significantly associated with the survival of NSCLC patients after radiotherapy [85]. Moreover, the level of circulating TGF-β1 was higher in lung cancer patients and persistent of high level was correlated with poorer prognosis, further suggesting STIE TGF-β1 as an immunosuppressive biomarker [86].

**IDO in STIE on TIME and tumor response to PD-1 inhibitor immunotherapy**

IDO, a well-known immunosuppressive immune checkpoint molecule, catalyzes the breakdown of tryptophan (Trp) to kynurenine (Kyn), and its expression is also heterogeneous in STIE [87]. Various IDO inhibitors have been attempted in clinical trials for cancer immunotherapy [88]. It has been shown that IDO1+ macrophage population is enriched in patients with NSCLC progression [89]. Figure 3 shows the multiple roles of IDO on TIME and STIE. Markers of IDO activity were reported as predictors of treatment outcomes for NSCLC patients. Botticelli et al. found that higher IDO activity in circulating blood revealed the resistance to PD-1 inhibitor immunotherapy in lung cancer which suggested the potential benefit of PD-1 inhibitor immunotherapy combined with IDO inhibitors in patients with higher IDO [37]. We recently found that among 116 NSCLC patients, changes in IDO metabolites levels after treatment predicted treatment outcomes [90]: (1) Baseline IDO activity was predictive of OS, and higher IDO activity was associated with a higher risk of distant metastasis and shorter survival time; (2) the ratio of kynurenine after/before radiotherapy could be used as biomarker for immune status during radiotherapy. Measurements of these immunomodulatory metabolites could predict OS in patients with NSCLC [90, 91]. In early NSCLC patients receiving definite radiotherapy, elevated IDO activity was associated with poor survival outcomes [90]. According to the IDO levels, the immunosuppressive effects of hypo-fractionated stereotactic body radiotherapy (SBRT) were lower than that of three-dimensional conformal radiation therapy (3D-CRT) [91]. These clinical data are examples that demonstrate the predictive and prognostic potential of STIE immunomodulatory factors in terms of patient and treatment outcomes.

Like TGF-β1, the IDO signaling pathway is upregulated in patients with progressive disease. Bivona et al. [89] compiled a list of 49 clinical biopsy samples from 30 NSCLC patients before and after targeted therapy. Patients with responsive disease showed alveolar regeneration cell signals, suggesting treatment-induced transformations of the original cell state. Patients with disease progression have upregulated IDO signaling pathways. Further studies have found that the failure of combination immunotherapy with IDO inhibitors and PD-1 inhibitors may be due to tumor immune microenvironment status being ignored [89]. A study showed that, under the background of anti-CTLA-4 immunotherapy, host-derived IDO can inhibit the infiltration and accumulation of tumor-reactive T cells in B16 melanoma tumors and weaken the anti-tumor efficacy. Growth of B16 melanoma was considerably delayed compared to wild-type mice, and overall survival rate was improved in IDO knockout mice treated with anti-CTLA-4. IDO deficiency also has synergistic effects with immunotherapy targeting PD-1/PD-L1 and glucocorticoid-induced tumor necrosis factor receptor. Furthermore, the experimental results showed that the overexpressed IDO tumors were resistant to CTLA-4 treatment, but not to CTLA-4/indoximod (IDO inhibitor) combination treatment [92]. There were also reports showing circulating IDO level correlations with overall survival, progression-free survival, and distant metastasis of patients with breast cancer, lung cancer, melanoma, and glioblastoma [90, 91, 93, 94]. These discoveries are informative and may facilitate the design of personalized treatment plans of immunotherapy.

**Artemin in STIE on TIME and tumor response to PD-1 inhibitor immunotherapy**

Artemin is a neurotrophic factor in the glial cell line-derived neurotrophic factor (GDNF) family of ligands within the TGF-β superfamily of signaling molecules. Artemin is also involved in the regulation of the tumor progression and tumor responses to cancer therapies, including immunotherapy and radiotherapy. The Artemin receptor is GDNF family receptor alpha-3 (GFRα3) which in itself cannot transmit signals to the cell, but passes signals when binding to Artemin to recruit the co-receptor RET and subsequently enters the cell through RET tyrosine kinase activity [95]. In hepatocellular carcinoma, Artemin inhibits tumor cell apoptosis and
promotes its migration by upregulating the expression of TROIBP and ITGB5 [35]. Tumor-inducible, erythroblast-like cells (Ter-cells) with Ter-119^+CD45^−CD71^+ markers deriving from megakaryocyte-erythroid progenitor cells produces Artemin in the spleen and leads high level of Artemin in the blood [35]. Studies have shown that Artemin enhances the resistance of lung cancer cells to radiotherapy through the TWIST1-BCL2 pathway [96], suggesting that Ter cells may inhibit the therapeutic effects of radiotherapy through Artemin. Our group found that radiotherapy significantly reduced the number of tumor-induced Ter cells in the spleen of tumor-bearing mice and the peripheral blood of cancer patients [36]. In addition, in cancer patients and tumor-bearing mice, radiotherapy reduced the level of Artemin in serum and the expression of GFRα3 in tumor tissues [36]. Moreover, our studies also revealed that Artemin significantly inhibited the killing effect of CD8^+ T cells on tumor cells and reduced the effects of radiotherapy and PD-L1 inhibitor therapy on tumor growth [36]. The impacts of Artemin on PD-L1 inhibitor therapy and the underlying regulatory mechanisms need further research.

**Tumor neoantigens in STIE on TIME and PD-1 inhibitor immunotherapy**

STIE also contains tumor neoantigens, which are repertoire of peptides that displays on the tumor cell surface but not normal tissues and serve as strong immune...
modulators. New technologies that allow a quick screening of neoantigens in each patient and the production of personalized vaccines have broadened the clinical and research prospects. Smith et al. [97] reported 20 patients with resectable non-small cell lung cancer with PD-1 inhibitor before surgical resection. Using single-cell transcriptomics, they found dysfunctional TIL subpopulations that were unable to recognize tumor antigens, including mutation-related neoantigens. Mutation-associated neoantigen (MANA) was using specific T cell assays to identify MANA-specific T cell clones. Tumor neoantigen-specific T cells are related to the effects of PD-1 inhibitor immunotherapy. Therefore, monitoring the changes of neoantigen-specific T cells during PD-1 inhibitor immunotherapy may be helpful to evaluate the response of PD-1 inhibitor immunotherapy. Our group has previously adopted single-cell sequencing to analyze the characteristics of tumor neoantigen-specific T cell subsets and evaluated the correlation between the tumor neoantigen-specific T cells and PD-1 inhibitor immunotherapy response [98]. In our tumor neoantigen study, neoantigens derived from EGFR mutation were identified in patients with lung cancer and found to be related to the survival of the patients [98]. One would assume that MANA or treatment-related changes would play an important role in treatment response of ICIs. Further study is needed on this topic.

**TIME on PD-1 inhibitor immunotherapy efficacy**

The heterogeneity of the TIME is clearly one of the most important reasons for the various responses to PD-1 inhibitors. The impact of TIME on PD-1 inhibitor immunotherapy efficacy has been a focus of a recent review [21]. In brief, Chen and Mellman [99] first proposed the concept of “Cancer Immune Cycle,” which simplified tumor immunity into seven end-to-end steps, including (1) the release of tumor antigens, (2) the presentation of antigens, (3) the initiation and activation of T cells, (4) the migration of T cells, (5) the penetration of T cells into tumor tissues, (6) the recognition of tumor cells by T cells, and (7) the elimination of tumor cells. All the above steps are indispensable, function interactively with various components of TIME, and jointly in concert with STIE, outline the complex response of the immune system to tumors. In addition to the genetic differences of the tumor itself, the immune systems of different patients are dissimilar, which is one of the important reasons behind the differences observed in the efficacy of PD-1 inhibitors in different patients [100]. The immune response triggered by effective and ineffective immunotherapy was compared in a triple-negative breast cancer. It was reported that the ineffective group mounted a short-term immune response toward the tumor, while the effective group mounted a coordinated immune response between different tissues including lymph nodes, bone marrow, and blood [101, 102]. Clearly, these phenomena are not explained by the activated immune cells, and one may hypothesize that the immune regulators in the STIE play an important role. The differential responses to immunotherapy heavily rely on each process of the “Cancer Immune Cycle” which also links the interaction between TIME and STIE [103].

**STIE and TIME in brain metastasis and PD-1 inhibitor**

Cancer metastasis is the major problem associated with cancer mortality. Brain metastasis (BrM) is a major problem for all cancers and accounts for about 20% of patients with solid tumors. Once a patient develops BrM, their prognosis is usually poor with an average survival time of less than 6 months. Nowadays, surgery, chemotherapy, and radiotherapy are the main treatments for BrM patients, though they are mostly not curative. As the toxicities and side effects of the above-mentioned treatment methods are common in brain tissues, PD-1 inhibitor immunotherapy offers a novel approach for treating BrM patients more effectively. The OAK study [104] found that PD-L1 inhibitor monotherapy for NSCLC patients with brain metastases reduced the risk of death compared with chemotherapy (median OS, mOS: 20.1 months vs 11.1 months) and delayed the time of new brain metastases in patients with baseline brain metastases. A meta-analysis of brain metastasis subgroups [105] found that PD-1 inhibitor immunotherapy was beneficial compared with chemotherapy in terms of mOS (8.4 months vs 6.2 months) and the incidence of new intracranial lesions (13% vs 17%) [105–107]. The clinical trials of combination immunotherapy found that PD-1 inhibitor combined with chemotherapy significantly improved the mOS of patients with NSCLC brain metastases when compared with chemotherapy alone (19.2 months vs 7.5 months) [108]. In a study investigating the use of concurrent radiotherapy combined with PD-1 immunization, the inhibitor treatment group had significantly prolonged OS (24.7 months) when compared with the non-synchronous combination therapy group (14.5 months) and the radiotherapy group (12.9 months) (P=0.006) [109]. However, due to the heterogeneity and immunosuppressive characteristics of the TIME of brain metastases and STIE of the patients, the overall effective rate of immunotherapy is still low. The specific mechanism of immunotherapy through the blood–brain barrier is poorly understood. As shown in Fig. 4, the connection between STIE and TIME was established by immune cells and their secreting immune modulating factors such as Kyn, TGF-β1, and Artemin. The STIE and TIME studies for brain metastases are limited. One study showed that the
immune cells of brain TME are largely determined by a specific tumor type rather than a central nervous system which has the “immune-privileged niche” [110]. Brain metastases from distant organs contain higher regulator T cells in the TIME. By contrast, gliomas-derived metastases presented abundance of tumor-associated macrophages [110]. A study on brain metastases with PD-1 inhibitor immunotherapy found that the responders had increased T cells and dendritic cells [111]. Indeed, further studies of the mechanisms that regulate the distribution and function of TIME immune cells and STIE in brain metastases are needed to provide a way to improve the immunotherapy efficacy.

**STIE/TIME cancer stem cells and their responses to PD-1 inhibitor**

Regression and progression of cancer after PD-1 Inhibitor are clearly a result of a complicated interaction between cancer cells and TIME cells, under a concerted regulation of STIE. Cancer stem cells (CSC), a special group of cells in tumors that maintain self-renewal and can differentiate into other tumor parenchymal cells, can also indirectly promote tumor development by attenuating immune surveillance [112]. CSCs are derived from the non-malignant stem or progenitor cells which are usually inhibited by Notch, WNT, Hedgehog, and Hippo signaling [113–115]. Xenotransplantation experiments have shown that even if one CSC enters the immunodeficient mice, tumors can be formed [116]. In vitro studies have shown that CSC has high expression levels of drug transporters [117, 118] and anti-apoptotic proteins [119, 120], low oxygen free radical levels [121–123], strong ability to repair DNA damage [124, 125], and slow proliferation rate [121, 126]. CSC can stay in a dormant state for a long time with self-renewal ability and plasticity, which can produce heterogeneous tumor cells.
and contributes to tumor recurrence and metastasis [127, 128]. Studies have shown that CSC expresses high levels of PD-L1 and induces T cell apoptosis by binding to its cognate receptor PD-1 on T cells in breast cancer, colon cancer, head and neck squamous cell carcinoma, and lung adenocarcinoma. More PD-L1 is enriched in CSC abundant patients than non-CSC abundant patients [129]. Currently, targeting Notch, WNT, Hedgehog, and Hippo signaling pathways can inhibit CSC, and a number of clinical trials have been carried out [130]. PD-1 inhibitor immunotherapy combined with targeted CSC therapy improved the effect of anti-tumor therapy [131, 132], which suggests that CSC is one of the potential factors for the failure of PD-1 inhibitor immunotherapy. However, how CSC leads to the failure of PD-1 inhibitor immunotherapy is still unclear. As CSC leads to a highly heterogeneous tumor immune microenvironment, single-cell multi-omics testing is long needed ideal technique to study the role of CSC in TIME. Our unpublished single-cell sequencing data found that CSC could highly express TGF-β1, which recruits MDSC, and subsequently form an immunosuppressive TIME. Meanwhile, PD-L1 was also highly expressed in CSC which aids in immune surveillance evasion, which explains the molecular mechanisms of tumor dormancy. Furthermore, the presence of TGF-β1 and IDO in STIE is heterogeneous, i.e., there are differences in TGF-β1 and IDO in tumors with different malignant degrees, indicating that their responses to treatment (at a proteomic level) were also heterogeneous.

There are many factors and cells in TIME and STIE related to the failure of ICI. Traditional low-throughput detection methods might not be able to reflect the heterogeneity of the TIME between different tumors and within one tumor. Single-cell transcriptomic and spatial transcriptomic testing of TIME and STIE will provide more insight that may lead to a potential solution. The results of single-cell omics can reveal the response mechanisms of the tumor cells to PD-1 inhibitor immunotherapy and identify predictive biomarkers for more effective treatment.

**STIE and TIME in hyperprogressive disease following PD-1 inhibitor therapy**

Hyperprogressive disease (HPD) refers to cases that the volume of the tumor lesion does not decrease but increases after immunotherapy, with a faster disease progression (typically at least two times) compared to before treatment [133, 134]. HPD induced by PD-1 inhibitor immunotherapy is another challenge for immunotherapy alone in addition to their low response rate. Among tumor patients receiving PD-1 inhibitor immunotherapy, 4–29% of patients develop HPD (approximately 13% of lung cancer) [135, 136]. It is unclear that which factors during PD-1 inhibitor immunotherapy contribute to the HPD. One study found that samples from cancer patients experiencing HPD had a greater number of tumor-associated macrophages [137]. It has been suggested that Fc receptors (antibody Fc receptors on the surface of cells such as macrophages) in TIME may be involved in this process. The possible mechanism is checkpoint inhibitor binding to this Fc receptor on macrophages and then inhibits the polarization of macrophages to the M2 subtype, thereby promoting the tumor growth [137].

Cancer genetic variation may play a significant role. Studies have found that 20% of cancer patients with EGFR mutations are more likely to have HPD. This proportion increases to 50% in patients with MDM2 mutations and 67% in patients with MDM4 mutations [138]. Our research team also analyzed the genomic mutation data of tumor patients in the early stage and found that the amplification of CCND1/FGF3/FGF4/FGF19 was prone to develop HPD (unpublished data). In addition, the immune cells and immune regulatory factors in the local tumor environment and circulating blood are directly related to the efficacy of immunotherapy and are also the main contributors to the progression of the disease. We analyzed the STIE of HCC patients treated by immunotherapy and found that patients who did not respond to immunotherapy had higher CD4+ T cells and Th17 cells and lower CD8+ T cells (unpublished data). If specific molecules involved in HPD are identified, strategies to reduce PD-1 inhibitor immunotherapy-related deaths can be developed to improve the survival rates of potentially responsive patients. Due to concerns about HPD, immunotherapy is frequently restricted to cancer patients without genetic mutations. Moreover, it is important to distinguish the exact roles of PD-1 inhibitors between HPD and pseudoprogression cases.

Single-cell genomics research may identify some novel perspectives of TIME and STIE for this previously unanswered clinical problem. Single-cell transcriptomic data on the patients who undergo HPD show that TGF-β1, IGF-1, ERK/MAPK, and PI3K/AKT signaling pathway were activated in tumors. A subpopulation of innate lymphoid cells named ILC3 cells increased in cancer patients with HPD after PD-1 inhibitor immunotherapy. Besides, the immunogenicity decreased in HPD tumors after therapy [139]. HPD tumors were infiltrated with more PD-1+ Treg than PD-1+ effector T cells which led to exacerbated growth in gastric cancer [140]. However, there is still a lack of research on the molecular mechanisms behind HPD in PD-1 inhibitor immunotherapy and the biomarkers to predict HPD. The role of STIE and its interaction with TIME deserve further study.
STIE, TIME, and side effects of PD-1 inhibitor therapy

PD-1 inhibitor immunotherapy can trigger adverse autoimmune reactions, which are called as immune-related adverse events (irAEs), characterized by the infiltration of T cells in various organs, including skin, colon, liver, lung, and endocrine organs. IrAEs significantly affect the survival time and quality of life in cancer patients [141]. A pooled analysis of 125 randomized clinical trials involving 20,128 patients found that 2/3 of the patients experienced at least one irAE after PD-1/PD-L1 inhibitor treatment. A small percentage of patients (0.45%) even died of irAE (with pneumonitis being the most common cause of death [28%]) [142, 143].

Cytokines in STIE play a critical role on irAEs, and its significance can be exemplified by the cytokine release syndrome (CRS), a fatal inflammatory reaction after PD-1 inhibitor immunotherapy. Patients with CRS may experience clinical symptoms such as low blood pressure, fever, headache, nausea, and diarrhea, in serious cases with encephalopathy, hypotension, hypoxia, liver dysfunction, and coagulation dysfunction. With the development and widespread use of immunotherapy, more and more tumor patients who received immunotherapy reported to have experience of CRS. In 2017, a patient with extensive metastatic alveolar soft sarcoma who received PD-1 inhibitor immunotherapy developed serious CRS symptoms. This is the first case of cytokine release syndrome in a patient receiving targeted treatment with PD-1 [144]. Gao et al. [145] found that esophageal cancer (ESC) patient developed irAE including CRS after PD-1 inhibitor therapy and had diarrhea, thrombocytopenia, and multi-organ injury. However, in this case, CRS occurred during radiotherapy after PD-1 inhibitor therapy, suggesting that the combination of PD-1 inhibitors and radiotherapy may lead to a greater risk of developing CRS [145]. However, another case report showed that the irAEs of immunotherapy combined with radiotherapy were far less than those of immunotherapy combined with other treatments such as chemotherapy and targeted therapy [146], likely due to various radiotherapy technologies. At present, there are few studies on CRS induced by PD-1 inhibitor immunotherapy under the widespread use of PD-1 inhibitors. It is necessary to carry out relevant evaluations and unravel the underlying immune-related risk factors. The characteristic of STIE and TIME of irAE needs more clear clarification to prevent the irAE.

Therapeutic strategies to reshape the STIE and TIME

Reshaping the STIE and TIME with local radiotherapy

Cancer treatment can induce changes in SITE and TIME which have subsequent effects on immunotherapy. Radiotherapy is one of the strongest treatment modalities to trigger an immune response. Local radiotherapy can modify the TME and TIME and regulate STIE through multiple biologic mechanisms. From the seven end-to-end cancer immune steps of Chen and Mellman [99], radiotherapy can modulate TIME and STIE at least through the following corresponding steps: (1) kill tumor cells to produce immunogenic tumor neoantigens, (2) alter cell surface molecules to facilitate antigen presentation, (3) regulate immune effector cells, (4) induce production of immune modulating cytokines to attract immune potent cells to the tumor sites, (5) help immune cells penetrating into tumor tissues, (6) open the communication between CSC and TIME, and (7) induce production of immune modulating molecules such as TGF-β1 and IDO. Figure 5 demonstrates the transformation of the “Cold” to “Hot” immune environment after radiotherapy. An appropriate dose of focal radiotherapy can stimulate the tumor antigens to CD8+ T cells in the proximal TIME and have further effect on the distal sites through STIE [147]. Indeed, radiotherapy can activate anti-tumor immune responses, and combination with radiotherapy has become one of the important ways to improve the effectiveness of PD-1 inhibitor immunotherapy [148]. However, combination therapy with radiotherapy and CTLA-4 inhibitors gave objective responses in only 18% of the enrolled patients and 31% of patients suffered from lung cancer patients [149]. Mechanistically, radiotherapy combined with PD-1 inhibitor immunotherapy can modulate immune function through various biology rationales including activating IFN-β, increasing the activity of CD8+ T cells in peripheral blood, and produce an abscopal effect [149]. The specific reshaping functions of radiotherapy on STIE and TIME are shown in Table 2, using NSCLC, HCC, and NPC as examples. In general, radiotherapy disrupted immune cell infiltration and induced de novo inflammation in the TIME. Theoretically, radiotherapy would be beneficial to patients with “Cold” TIME rather than the “Hot” TIME as the radiotherapy may damage existing CD8+ T cells [150]. In addition, radiotherapy can prompt the PD-L1 expression in tumor [150] and trigger the activity of STIE through circulating immune cells such as CD8+ T cells [53]. Lan et al. [151] also demonstrated that when RT combined with bintrafusp alfa (BA), a bifunctional functional protein targeting PD-L1 and TGF-β1 can reshape the TIME and STIE and stimulate tumor-killing immune reactions. Specifically, BA combined with RT (BART) can enhance the anti-tumor activity, weaken tissue fibrosis, and increase tumor-infiltrating leukocytes in a variety of mouse tumor models with poor immune infiltration. For example, in the KPC mouse model, BART was able to further reduce the 18 F-FDG SUVmax relatives to BA or RT.
monotherapy and further delay tumor growth. In emT-6 models, BA reduced α-smooth muscle actin (α-SMA), a marker of CAF activation, and collagen deposition, and increased CD8+ TIL [152]. Although RT significantly increased α-SMA levels, BA reversed RT-induced α-SMA and collagen deposition. It was also found that BA significantly reduced RT-induced epithelial–mesenchymal transformation (EMT), ECM, fibrosis, and vascular endothelial growth factor (VEGF) expression. Apparently, BA and RT have synergistic activity, that is, BA can further enhance the positive immune modulation effect of RT, while reversing the negative effect of RT to some extent, leading to local remodeling of TME and enhancing the immune response.

In a joint experiment comparing stereotactic body radiotherapy (SBRT) of hypofractionated treatment with different immune checkpoint inhibitor (CTLA-4, PD-1 inhibitors) therapies, radiotherapy combined with PD-1 inhibitors resulted in longer disease-free survival than that of radiotherapy combined with CTLA-4 inhibitor...
Table 2  Reshaping STIE and TIME with radiotherapy

| Cancer type | STIE | TIME | Cell | Immune regulator | Cell | Immune regulator | REF |
|-------------|------|------|------|------------------|------|------------------|-----|
| NSCLC       | ↑: CD8⁺ T, CD4⁺ T, NK, B cell, CD3³⁻ immune cell, γ-H2AX foci PBL | ↑: T cell repertoire, Effector T, DC, N2 neutrophil, M2 macrophage, MDSC; ↓: NK, Trending in TIL | ↑: ssDNA, IFNs, STING/TLK1 pathway, MIF-1α/CC13 | ↑: TGF-β, IFN-γ, PD-L1, ICAM-1, MHCI-I, Fas, CSF-1, SDF-1, GFRA3, CCL2, CXCL16, PD-L1 on cancer cell | ↑: PD-1, IFN Receptors, CXCL10, CXCL16 | [33, 35, 36, 91, 155–166] |
| HCC         | ↑: TNF-α, NK, CD3⁺CD56⁺NKT-like cell | ↑: CD4⁺ CD25⁺ T, CD4⁺ CD127⁺ T | ↑: PD-L1, AFP, ALB, TNF-α | TGF-β, MHCI-I, PD-L1, PD-L1 on cancer, IFN-γ produced by dLN CD8⁺, CD4⁺ T | ↓: HIF-1α | [53, 156, 158, 159, 162, 167–171] |
| NPC         | ↑: CCR4⁺ CD8⁺ T | ↑: CCL22 | ↑: pEBV, miR142-5p | ↑: TGF-β, PD-L1, MHCI-I, PD-L1 on cancer | ↑: PD-1, IFN-γ, STING, TBK1 pathways, MIP-1α/ICAM-1, MHC-I, PD-L1, IFN-γ, TNF-α, MDC | [156, 158, 159, 172–174] |

CTC circulating tumor cells, T cells, NK: natural killer, DC: dendritic cell, dLN: tumor draining lymph nodes, Ter-cells: tumor-inducible, erythroblast-like cells, NLR: neutrophil-to-lymphocyte ratio, ALB: albumin, AFP: alpha-fetoprotein, ALC: absolute lymphocyte count, MDC: macrophage-derived chemokine, PBL: peripheral blood lymphocytes, TIL: tumor-infiltrating immune cell (e.g., lymphocyte, APC antigen-presenting cells), pEBV: plasma Epstein–Barr virus; ↑: upregulation; ↓: downregulation; - symbol, no significant change in the cited literature studies; ↑, ↓ and - reflected the changes in tumor tissue or cancer patients compared with adjacent normal tissue or non-cancer donors; REF reference

treatment [149, 155]. In terms of liver metastases, however, Zou et al. [53] found that patients with liver metastases have restricted benefits from immunotherapy with PD-1 inhibitors. In a mouse liver metastasis model, through single-cell transcriptomic analysis for the detection of tumor liver metastasis, activated CD8⁺ T cells in the systemic circulation, the number of peripheral T cells, and the diversity and function of tumor T cells were shown to be decreased [53]. Through the shortage of CD8⁺ T cells and peripheral tolerance mechanisms in the host, liver metastases may cause resistance to adaptive immunotherapy. The combination of liver-directed radiotherapy and PD-1 inhibitor immunotherapy may promote systemic anti-tumor immunity. Liver-directed radiotherapy also reshapes the liver immune microenvironment, prevents the liver siphoning effect of T cells, and restores the therapeutic effect of PD-1 inhibitors in the liver metastasis model.

Our previous work has also demonstrated radiotherapy immunomodulatory effects [67], consistent with results of a meta-analysis of 18 studies (involving 7219 lung cancer patients) [175]. Patients with a high number of lymphocytes and a low ratio of neutrophils to lymphocytes (NLR) in STIE before treatment showed higher overall survival following RT [67]. Analysis of the different stages of tumors found that patients with low NLR have higher survival rates across all stages of tumors [67]. As previously mentioned, the metabolites of IDO changed heterogeneously during radiotherapy; those with IDO activity decreased had significant better survival outcomes and less distant metastasis in lung cancer patients [90, 91].

Radiotherapy modulation effects on IDO immune status were heterogeneous with radiation doses and radiation technology. IDO activity first decreased after low doses of radiotherapy in most patients; at the end of treatment with high dose of treatment, some of them increased and some remained unchanged or decreased; the latter one had better outcome. Patients treated with SBRT (more conformal treatment, less normal tissue radiation therapy) kept IDO level unchanged and had better survival, compared to less conformal 3D-CRT radiotherapy which increased IDO level in more patients [91]. Further studies are also needed to identify the underlying T cell and IDO pathways to answer questions including: which subtypes of T cells are involved in tumor control or progression? What are the factors that control these immune cells? What is the relationship between T cells and IDO metabolites? Studies have found that radiotherapy reduces the total count across all types of lymphocytes, such as CD4⁺ T cells, CD8⁺ T cells, B cells, and NK cells in STIE [176]. The use of STIE and TIME to predict possible adverse immune reactions deserves further study. Our team is currently investigating the changes in TIME and STIE of various types of cancer patients during PD-1 inhibitor immunotherapy and combined PD-1 immunotherapy with radiotherapy.

**Reshaping STIE and TIME with immunotherapy**

Immunotherapy can change STIE and TIME. Most of this work is on the fate of T cell which is critical in the process of the reshaping of STIE and TIME with immunotherapy. T cell exhaustion is currently a major obstacle
Table 3  Reshaping STIE and TIME with immunotherapy

| Cancer type | STIE                                                                 | TIME                                                                  | REF |
|-------------|---------------------------------------------------------------------|-----------------------------------------------------------------------|-----|
| NSCLC       | ↑: PD-1+CD8+ T, Ki-67+                                             | ↑: Antigen-specific CD8+                                             | [179, 193–204] |
|             | PD-1+CD8+ T, ICOS+                                                 | ↓: Exosomal PD-L1                                                     |     |
|             | CD4+ T, Neoantigen-specific T                                       | (Patients responding to PD-1 inhibitor therapy)                       |     |
| HCC         | ↑: CD8+ T, CD3+CD56+ NKT, CXCR3+CD8+ Treg, APC                    | ↑: TOX+ T, CD8+ PD1+ CXCR+ T, TNF+ T, CD3+CD56+ NKT, CD39+CD5+ TIL | [54, 55, 205–211] |
| NPC         | ↓: EBV-specific T                                                   | ↑: IFN-γ                                                             | [212–214] |
|             |                                                                     | ↓: IFN-β-dependent NK                                                |     |
|             |                                                                     | ↓: CCR4+ Treg                                                        |     |

*T cells, N/K natural killer, DC dendritic cell, TIL tumor-infiltrating immune cell (e.g., lymphocyte, APC antigen-presenting cells); Texp effector memory T; Treg precursor exhausted T, EBV Epstein–Barr virus; TRAIL tumor necrosis factor-related apoptosis-inducing ligand, ↑, upregulation; ↓, downregulation; - symbol: no significant change in the cited literature studies; ↑, ↓ and - reflected the changes in tumor tissue or cancer patients compared with adjacent normal tissue or non-cancer donors; REF reference

limiting the efficacy of T-cell-based immunotherapy [177]. The developmental hierarchy of exhausted CD8+ T cells (Tex) can be divided into four-stage according to transcriptional and epigenetic analyses, namely quiescent resident stage, proliferative circulating stage, circulating mildly cytotoxic stage, and terminally exhausted resident stage. Both quiescent resident and proliferative circulating stages with marked TCF1-TOX were reversible upon immunotherapy [178]. There are three potential reasons to explain the increase in tumor-specific T cell precursors after effective PD-1 inhibitor treatment: 1. reversal of exhausted CD8+ T cells, 2. expansion of preexisting precursor cells in the tumor immune microenvironment (TIME), and 3. T cells supplied from outside TIME such as the peripheral blood (STIE) [179]. The reversal of exhausted T cells may not be abundant in the PD-1 treatment responsive group as the previous mouse studies have shown that the epigenetic modifications and characteristics of exhausted T cells are stable and difficult to change [179, 180]. The clonal replacement of T cells was observed in exhausted CD8+ T cells and evident in patients with basal or squamous cell carcinoma [181]. In addition, Yost et al. found that the preexisting tumor-specific T cells in TIME were insufficient to reinvigorate and PD-1 treatment-responsive T cells were derived from the distinct clonal T cells which just entered the TIME [181]. Furthermore, Liu et al. found that exhausted T cells were unlikely to be derived from the reinvigoration of terminally exhausted cells; instead, they were accumulated by (1) local expansion and (2) replenishment by peripheral T cells with both new and preexisting clonotypes [179, 181].

Although PD-1 could reinvigorate exhausted CD8+ T cells [179, 181, 182], this immune therapy cannot revise the exhaustion-associated epigenetic imprint [180]. Effector-like TOX, TOX2, AP-1, and RGS16 proteins play a key role in the regulation of T cell exhaustion in relation to the transcriptional and epigenetic aspects [177, 183–186]. The specific reshaping of STIE and TIME by immunotherapy is shown in Table 3, using NSCLC, HCC, and NPC as example tumors. The exhausted T cells appeared after PD-1 inhibitor treatment [187–189]. The loss of T cell regulator such as IL-2 regarding as T cell growth factor is accompanied with T cell exhausted phenotype after PD-1 inhibitor treatment in NSCLC [190, 191]. In clinical practice, T cell exhaustion is a major limiting factor of PD-1 and chimeric antigen receptor (CAR)-T cell therapeutics. Weber et al. designed a drug switch to regulate CAR signal to temporarily inhibit T cell activity, which helped preventing CAR-T cell being exhaustion and was able to effectively improve CAR-T cell’s anti-tumor activity in mouse models [192]. Furthermore, combining PD-1 inhibitors with CAR-T immunotherapy can help reverse the effects of Tex.

Reshaping the STIE and TIME with chemotherapy, targeted therapy, or combined therapy

Cancer treatment can reshape the STIE and TIME which can conversely impact the curative effect of subsequent immunotherapy (Fig. 5). Systemic therapeutic approaches such as chemotherapy can also turn “cold tumors” into “hot tumors” [154]. The reshaping after systemic therapy is apparently complicated and varies with tumor types. Using NSCLC, HCC, and NPC as example tumors, the heterogeneous changes of STIE and TIME after cancer systemic chemotherapy and targeted therapy are summarized in Table 4. Chemotherapy has extensive cytotoxic effects on highly proliferating cells, especially
Table 4 Reshaping STIE and TIME with chemotherapy, target therapy, or combined therapy

| Cancer type | STIE | TIME | REF |
|-------------|------|------|-----|
| NSCLC       | ↑: CD8⁺ T, Th1 cell, PD-1⁻⁺CD8⁺, PD-1⁻⁺CD4⁺, CD-3⁺CD8⁺ T, Treg, Th2 cell, Th17 cell, NK | ↑: T cell, CD8⁺ T, Senesc-cent CD28⁻ CD57⁺ T, Highly differentiated CD8⁺CD28⁺ T, DC: CD8⁺ TIL density in tumors with a high PD-L1 expression level | [198, 215, 226–228] [216, 217, 229–231] |
| HCC         | ↑: CD14⁺⁺ Monocyte, CD56⁺ NK | ↑: T cell proliferation and tumor infiltration, CD8⁺ T, CSC | ↑: IL-1β, CXCL5, HIF-1α/2α, IL-6, FGFR4, LIF, AKT1/STAT3, PD-L1/METTL3 on cancer | [211, 228, 232–239] [240, 241] |
| NPC         | ↓: CD3⁺⁺⁺ CD4⁺⁺⁺ CD8⁺⁺⁺ T, CD8⁺⁺⁺ T | ↑: CK-19, S-LDH | ↑: PD-1, PD-L1, IL-2, IL-6, CEBPA, miR-3188/ PD-L1 on cancer | [228, 242–248] |

T cells, CSC cancer stem cell, NK natural killer, DC dendritic cell, AFP alpha-fetoprotein, ALC absolute lymphocyte count, TIL tumor-infiltrating immune cell (e.g., lymphocyte, APC antigen-presenting cells); CK-19 cytokeratin-19, S-LDH serum lactic dehydrogenase, ctDNA circulating tumor DNA; ↑, Upregulation; ↓, Downregulation; -, symbol: No significant change in the cited literature studies; ↑, ↓ and - reflected the changes in tumor tissue or cancer patients compared with adjacent normal tissue or non-cancer donors; REF reference

on the hematopoietic and immune systems. Chemotherapy can also compromise PD-1 inhibitor therapy, from cytotoxicity on the immune cells [150]. Targeted therapy through small molecular inhibitor mainly functions in the rapidly growing tumor cells. Compared with chemotherapy, targeted therapy inhibits tumor growth without adversely affecting the immune system, making it a potential option in combination with PD-1 inhibitor therapy [150]. It is also noted that chemotherapy agent cisplatin and targeted drugs like crizotinib (ALK and ROS1 inhibitor) can also induce similar immunogenic cell death and both increase CD8⁺ T cell infiltration [215]. For combined immunotherapy, a preclinical study on the Lewis lung carcinoma tumor model showed that combination therapy of IDO inhibitor with radiotherapy can reduce the expression of PD-L1 and Treg and promote the maturation of dendritic cells in the TME. This shows that combined therapy can enhance the activity of T cells and promote anti-tumor immunity [216]. In a study of C57BL/6 xenotransplantation mouse model of lung cancer, although radiotherapy alone increased the infiltration of Treg and cytotoxic T cells, the combination of radiotherapy and PD-1 inhibitor immunotherapy can effectively inhibit tumor progression, increase CD8⁺ T cells, and reduce MDSC and iTreg [217]. The experimental results of an in situ tumor-bearing mouse model showed that after PD-1 inhibitor therapy combined with radiotherapy, the ratio of CD4⁺⁺⁺ CD8⁺⁺⁺ T cells, neutrophils, IFN-γ, TNF, and IL-5 in the lung tissue of the mouse model increased, and inflammatory reactions increased [218]. In the mouse HCC model, the survival rate of PD-1 inhibitor immunotherapy combined with radiotherapy was significantly improved, which greatly inhibited the growth of tumor, increased CD8⁺ T cells, and restored their function [219]. Cytokines and chemokines are soluble proteins produced by a variety of cells, which have a wide range of regulating functions and influence cancer immunotherapy. Reactive CCL4 through inhibiting epigenetic regulators such as HDAC8/SIRT7 with combination of PD-L1 inhibitor therapy may enhance tumor killing in HCC [54, 55]. Interferon-α (IFN-α) could promote tumor apoptosis and inhibit tumor cell proliferation. Interleukin-15 is produced primarily by activated bone marrow cells. Compared with PD-1 inhibitor alone, combined application of PD-1 and LAG-3 inhibitors may improve the anti-tumor function of CD8⁺ T cells [220]. The overactivation of TGF-β1 signal resists the PD-L1 inhibitor therapy in the TIME and STIE [221]. Targeting PD-L1 and TGF-β1 may improve the resistance condition [151]. The first human clinical trial of IL-15 showed that NK and CD8⁺ T cells were amplified in STIE (peripheral blood) of patients with advanced melanoma and patients with renal cell carcinoma (RCC), but with severe adverse reactions [222]. ALT-803 is another variant of IL-15, among 21 patients with NSCLC, 29% achieved objective response and showed elevated levels of circulating NK and CD8⁺ T cells through subcutaneous co-administration of PD-1 inhibitor therapy [223]. TNF-α is mainly produced by monocytes, macrophages, and DCs. It acts as a mediator of anti-tumor immune response in tumor.
immunotherapy. The results of an experiment in a mouse model showed that TNF-α blockade could overcome resistance to PD-1 inhibitor immunotherapy [224]. Overall, blockade of inhibitory receptors, costimulatory receptors, cytokines, immune checkpoints, and combined use of PD-1 inhibitor with more traditional tumor treatments, such as radiotherapy, chemotherapy, and targeted therapy, have all shown good anti-tumor efficacy, likely through reshaping the TIME and STIE [225].

**Single-cell and spatial transcriptomics in TIME and STIE research**

The technique of next-generation sequencing (NGS) has enhanced our understanding of the genomic effects on malignant tumor cells, but cannot accurately dissect individual effects of each TIME cellular components, which worked together to promote the carcinogenesis. Single-cell multi-omics may better analyze the relationship between spatial cell distribution characteristics and gene transcription expression in cancer patients TIME, and their dynamic changes during immunotherapy [249]. Single-cell RNA sequencing (scRNA-Seq) can characterize the transcriptome of each individual single cell and reveal the subpopulations of cells within a given specimen (tumor tissue for TIME or blood sample for STIE) [250]. However, in the necessary tissue dissociation step of scRNA-Seq, the separation of individual cells destroys their spatial positioning in original tissues and their close information to each other. Given that the function of proximal and paracrine signals ranges from 0 to 200 μm, this type of spatial information is essential for understanding the cell-to-cell communication between normal tissues and diseased tissues [250]. Spatial transcriptomics measures all gene activities in tissue samples and maps the locations where the activities occur, which can help us better understand the relationships between gene expression and cell positioning within the tumor tissues, providing the knowledge that single-cell genomics missed. Therefore, strategies combining single-cell transcriptome with spatial transcriptome have a potential to define the TIME and their responses to cancer therapy more precisely [251, 252]. More importantly, the combination of these two technologies may even recover the location of new cell groups in the TIME. Further studies of many cancer patients are needed to examine in-depth understanding of the heterogeneity STIE and TIME as well as dynamic changes after treatment, both of which help to promote precision combination immunotherapy to improve treatment outcome [253–256].

In a recent study of scRNA-Seq analysis in 47 tumors from 36 NSCLC patients, the PD-1 inhibitor immunotherapy-responsive group had significantly increased numbers of precursor exhausted CD8+ T cells (Texp), featured by the low expression of co-suppressor molecules and high expression of GZMK [257]. Meanwhile, a study of 29 stage IV NSCLC patients found positive association between the early increase in PD-1+ CD8+ T cells in the blood and clinical response to the PD-1 inhibitor treatment [258]. Using single-cell transcriptomic sequencing of the primary tumor specimens, a study 12 NSCLC patients treated with immunotherapy combined with EGFR-TKI treatment characterized 15 main cell types (including fibroblasts, endothelial cells, tumor cells, macrophages, T cells, B cells, mast cells, neutrophils, dendritic cells, and ciliated cells). There were high proportion of CD8+ T cells and low proportion of the M2/M1 macrophages in the good PFS group [259]. In a study of 7 lung cancer patients undergoing neoadjuvant immunotherapy, single-cell sequencing revealed a higher proportion of tumor-infiltrating T cells in general and lower myeloid cells compared to the group without neoadjuvant therapy. These patients had distinct different expression profiles in terms of leukocyte cell adhesion and cell cycle arrest [260], suggesting the importance of monitoring the TIME in immunotherapy. Another small clinical study of lung cancer samples before and after PD-1 inhibitor treatment found that the CD8+ tumor-infiltrating lymphocytes related to cytotoxic function (PRF1, GZMB, and GZMH) and activation (CD38) increased in post-treatment patients [261]. The tumor-associated CD4+ T cell clones in STIE peripheral blood have higher cytotoxic activity than the CD8+ T cell clones, but post-progressive CD8+ T cells can be observed in patients with disease progression. Moreover, T cell abundance decreased significantly, and the proportion of PD-1+ T cells decreased [262].

Single-cell sequencing analysis also found that the gene expression profiles were different between the PD-1 high and PD-1 low subpopulations of CD8+ T cells in NSCLC, and that the transcription factor TOX can effectively predict the overall survival and PD-1 inhibitor efficacy in NSCLC [263]. Single-cell sequencing of 7 liver cancer patients before and after immunotherapy found that paired tumor biopsies between malignant cells and between tumors of different patients have similar genome specificities, and the expression of SPP1 was significantly increased after treatment. Moreover, the proportion of CD4+ memory T cells in the treatment response group was higher [264]. The above data confirmed the utility of single-cell sequencing technology in the in-depth exploration of treatment response, disease progression, and biomarkers during immunotherapy for liver cancer and lung cancer.

Spatial transcriptomics (ST) will overcome the loss in the spatial pattern of transcriptomics of the single-cell sequencing technology. A study applied the ST
technology in the tumor tissues with 4 LUAD and 8 LUSC from 12 NSCLC patients, tracked the subclone of the specific sate of tumors through spatial pseudo time, and further described the process of epithelial–mesenchymal transition in detail [265]. Besides, the ST technology of 21 primary tumor tissues from 7 HCC patients found that the fibroblasts and endothelial cells can form a barrier-like capsules to prevent immune cell infiltration which may hinder immunotherapy [266]. In NPC, the efficacy of PD-1 inhibitor treatment can be improved by combination therapy, plus systemic therapy in first-line therapy [267] or radiotherapy [268]. However, due to the difficulty of obtaining samples before and after treatment, the evidence on TIME effect remains limited. Changes in specific immune cell subtype, abundance, time, and spatial correlation in immunotherapy are still obscure and need to be further strengthened. With advances in single-cell technology, studies on STIE and STIE modulating factors may enlighten this field of research quickly.

Conclusions
In summary, PD-1 inhibitor immunotherapy faces bottlenecks such as overall low response rate, hyperprogressive disease, limited understanding in brain metastasis, and serious irAE. Single-cell transcriptomic and spatial transcriptomic techniques can be used to study the
Fig. 7 A proposed study schema of STIE and TIME. The pipeline describes a proposed process of studying STIE and TIME including the different treatment strategies and clinical outcomes. The cross-validation of clinical patients and animal models will clearly reveal the STIE and TIME regulation in the RT and PD-1 inhibitor immunotherapy. As the massive data produced by STIE and TIME study, AI model will assist the analysis of data from an in-house or public research.
Table 5  Ongoing randomized clinical trial of testing combined therapy with PD-1/PD-L1

| NCT number   | Conditions                      | Experimental arms                                                                 | Control arm                                                                 | Phases      | Enrollment | Primary outcome measures                       |
|--------------|---------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------|------------|-----------------------------------------------|
| NCT03924869 | NSCLC (Stage I/II)              | SBRT + Pembrolizumab (Anti-PD-1)                                                  | SBRT + Placebo                                                            | Phase 3     | 530        | EFS, OS                                       |
| NCT03774732 | NSCLC (Stage IIIb/IIIC/IV)      | 3D-CRT/SABR + Pembrolizumab (Anti-PD-1) + Chemotherapy                          | Pembrolizumab (Anti-PD-1) + Chemotherapy                                 | Phase 3     | 460        | OS                                            |
| NCT05298423 | NSCLC (Stage III)               | Pembrolizumab (Anti-PD-1)/Vibostolimab Coformulation + Chemotherapy + Thoracic Radiotherapy | Chemotherapy + Thoracic Radiotherapy + Durvalumab (Anti-PD-L1)                  | Phase 3     | 784        | PFS, OS                                       |
| NCT03288870 | NSCLC (Stage IIIb/TNM Stage 4)  | BCD-100 (Anti-PD-1) monotherapy                                                    | Docetaxel monotherapy                                                                 | Phase 2     | 218        | OS                                            |
| NCT03150875 | NSCLC (Advanced/Metastatic)     | IBI308 (Anti-PD-1)                                                                | Docetaxel                                                                   | Phase 3     | 290        | OS                                            |
| NCT03922997 | NSCLC (Advanced/Metastatic)     | Atezolizumab (Anti-PD-L1)                                                         | /                                                                          | Phase 3     | 101        | SAER                                          |
| NCT02504372 | NSCLC (Stage IIb/IIIa)          | Pembrolizumab (Anti-PD-1)                                                         | Placebo                                                                   | Phase 3     | 1177       | DFS                                           |
| NCT03285763 | NSCLC (Advanced/Metastatic)     | Atezolizumab (Anti-PD-L1)                                                         | /                                                                          | Phase 4     | 619        | PAEs                                          |
| NCT03949231 | HCC (Advanced)                  | PD1/PDL1 inhibitor hepatic artery infusion                                         | PD1/PDL1 inhibitor vein infusion                                           | Phase 3     | 200        | OS                                            |
| NCT04738487 | NSCLC                           | Pembrolizumab (Anti-PD-1)/Vibostolimab (Anti-PD-1)                               | Pembrolizumab (Anti-PD-1)                                                  | Phase 3     | 1246       | OS, PFS                                       |
| NCT04331626 | NSCLC (Metastatic)              | Nivolumab (Anti-PD-1) + Low-dose Gemcitabine                                     | /                                                                          | Phase 4     | 50         | ORR                                           |
| NCT04205812 | NSCLC (Metastatic)              | Retifanlimab (Anti-PD-1) + Chemotherapy                                          | Placebo + Chemotherapy                                                     | Phase 3     | 530        | PFS, OS                                       |
| NCT03594747 | NSCLC (Advanced)                | Tislelizumab (Anti-PD-1) + Carboplatin + Paclitaxel                               | Carboplatin + Paclitaxel                                                   | Phase 3     | 360        | PFS                                           |
| NCT03663205 | NSCLC (Advanced)                | Tislelizumab (Anti-PD-1) + Platinum + Pemetrexed                                 | Cisplatin/Carboplatin + Pemetrexed                                        | Phase 3     | 334        | PFS                                           |
| NCT04702009 | NSCLC (Advanced)                | Anti-PD-1/PD-L1 Antibody + Chemotherapy + Bronchoscopy-assisted Interventional Therapy | Anti-PD-1/PD-L1 Monoclonal Antibody + Chemotherapy                        | Phase 2     | 80         | ORR                                           |
| NCT03178552 | NSCLC (Unresectable/Advanced/Metastatic) | Cohort A: Alectinib 600 Milligrams (mg) | Cohort C: Pemetrexed, Cisplatin or Carboplatin | Cohort B: Dose Finding Phase (DFP) Alectinib | Cohort C: Gemcitabine, Cisplatin or Carboplatin | Cohort C: Cisplatin or Carboplatin | Cohort E: Atezolizumab (Anti-PD-1), Vemurafenib, and Cabimetinib | Cohort F: Atezolizumab (Anti-PD-1), Bevacizumab, Carboplatin, and Pemetrexed | Phase 2 | 700 | PFS, TIR, ORR |
Table 5 (continued)

| NCT number   | Conditions                  | Experimental arms                                                                 | Control arm                              | Phases | Enrollment | Primary outcome measures |
|--------------|-----------------------------|-----------------------------------------------------------------------------------|------------------------------------------|--------|------------|--------------------------|
| NCT03976375  | NSCLC (Metastatic)          | Pembrolizumab (Anti-PD-1) + Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα)       | Docetaxel                                | Phase 3| 405        | OS, PFS                  |
| NCT04921358  | NSCLC (Advanced/Metastatic) | Tislelizumab (Anti-PD-1) + Sitravatinib (Anti-AXL, Anti-MER, Anti-VEGFR2, Anti-tPDGFR, Anti-KIT, Anti-RET, Anti-MET, Anti-DDR2, Anti-TRKA) | Docetaxel                                | Phase 3| 420        | OS, PFS                  |
| NCT03906071  | NSCLC (Advanced/Metastatic) | Nivolumab (Anti-PD-1) + Sitravatinib (Anti-AXL, Anti-MER, Anti-VEGFR2, Anti-tPDGFR, Anti-KIT, Anti-RET, Anti-MET, Anti-DDR2, Anti-TRKA) | Docetaxel                                | Phase 3| 532        | OS                       |
| NCT03829332  | NSCLC (Metastatic)          | Pembrolizumab (Anti-PD-1) + Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα)       | Pembrolizumab (Anti-PD-1) + Placebo     | Phase 3| 623        | OS, PFS                  |
| NCT04157985  | NSCLC (Advanced)            | Discontinue Treatment with PD-1/ PD-L1-1 inhibitor                              | Continue Treatment with PD-1/ PD-L1 inhibitor | Phase 3| 578        | PFS                      |
| NCT04229355  | HCC (Unresectable/Advanced) | DEB-TACE + Sorafenib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα)                      | DEB-TACE + PD-1 inhibitor                | Phase 3| 90         | PFS                      |
| NCT03062358  | HCC (Advanced)              | Pembrolizumab (Anti-PD-1) + BSC                                                 | Placebo + BSC                            | Phase 3| 454        | OS                       |
| NCT05307926  | HCC (Recurrent)             | PD-1 inhibitor                                                                   | TACE                                     | Phase 2| 655        | DFS, TEAEs               |
| NCT03867084  | HCC (Early)                 | Pembrolizumab (Anti-PD-1)                                                       | Placebo                                  | Phase 3| 950        | RFS, OS                  |
| NCT04167293  | HCC (Early)                 | SBRT + Sintilimab (Anti-PD-1)                                                    | SBRT                                     | Phase 2| 116        | PFS                      |
| NCT04709380  | HCC (Advanced)              | Radiotherapy + Toripalimab (Anti-PD-1)                                          | Sorafenib                                | Phase 3| 85         | TPP                      |
| NCT03605706  | HCC (Advanced)              | SHR-1210 (Anti-PD-1) + FOL-FOX4                                                 | SHR-1210 (Anti-PD-1) + Placebo          | Phase 3| 396        | OS                       |
| NCT03713593  | HCC (Advanced)              | Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα + Pembrolizumab (Anti-PD-1)        | Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα + Placebo) | Phase 3| 750        | PFS, OS                  |
| NCT03764293  | HCC (Unresectable/Advanced/Metastatic) | SHR-1210 (Anti-PD-1) + Apatinib (Anti-VEGF2)                                  | Sorafenib                                | Phase 3| 543        | OS, PFS                  |
| NCT05313282  | HCC (Advanced)              | Hepatic Arterial Infusion combined with Apatinib (Anti-VEGFR-2) and Camrelizumab (Anti-PD-1) | Apatinib (Anti-VEGFR-2) + Camrelizumab (Anti-PD-1) | Phase 3| 140        | PFS                      |
| NCT03427827  | NPC (Advanced)              | Camrelizumab (Anti-PD-1)                                                         | BSC                                      | Phase 3| 442        | FFS                      |
| NCT04376866  | NPC (Recurrent)             | CCRT + Toripalimab (Anti-PD-1)                                                   | CCRT                                     | Phase 3| 204        | OS                       |
| NCT04778956  | NPC (Resectable/Recurrent)  | Toripalimab (Anti-PD-1) + Salvage Surgery                                         | Salvage Surgery                          | Phase 3| 218        | DFS                      |
| NCT0443813   | NPC (Recurrent)             | Toripalimab (Anti-PD-1) + Concurrent Chemoradiotherapy                          | Concurrent Chemoradiotherapy             | Phase 3| 226        | PFS                      |
heterogeneities and orchestration between STIE and TIME, before and after treatment with PD-1 inhibitors, the impacts of metabolic neural pathways on TIME, their overall influences on the immune microenvironment, and individual effect of traditional cancer treatment like immune modulating radiotherapy. Studying the TIME of tumor in situ and metastatic sites, along with STIE in blood, is opening a big door for the mechanism of tumor progression and overall cancer treatment. Looking for the key factors in STIE and TIME may identify pathway to improve the treatment efficiency of PD-1 inhibitors. As more clinical trials continue, effective combination of radiotherapy and immunotherapy will continue to make great breakthroughs. More trial evidence with STIE correlative studies is needed to determine the sequence and timing of treatment for maximal clinical benefits.

**Questions and future directions**

Although new technologies single-cell multi-omics may solve many problems, cancer immunotherapy still faces many challenges. (1) When to use single-cell transcriptomic and spatial transcriptomic techniques to evaluate therapeutic effects of radiotherapy, surgery, chemotherapy, and immunotherapy as Fig. 6 shown? (2) Does PD-1 inhibitor immunotherapy alone or combined with other therapy could reshape STIE and TIME in the same direction? Do TIME and STIE reshape similarly in all cancer patients, and under all various conditions? (3) How to design inhibitors against the key targets in STIE and TIME to improve the treatment efficiency of PD-1 inhibitors? As the STIE and TIME may have opposite directions in anti-tumor therapy as Fig. 1 shown, biomarker-guided precision strategies should be considered. (4) For brain metastases which is associated with large-scope of STIE and TIME plus the blood–brain barrier, how to apply single-cell transcriptomic and spatial transcriptomic techniques to evaluate the key changes of nerve-related genes for improving tumor immunotherapy? In response to these problems, strategies of collecting full spectrum of data in STIE and TIME with inclusion of clinical patient and treatment details as illustrated in Fig. 7 will maximize the learning. As the expensive application of the single-cell transcriptomic and spatial transcriptomic techniques, mounts of integrated data from different centers are commonly used in one study to verify new findings. What’s more, single-cell

---

**Table 5 (continued)**

| NCT number       | Conditions | Experimental arms                                      | Control arm                                      | Phases | Enrollment | Primary outcome measures |
|------------------|------------|--------------------------------------------------------|--------------------------------------------------|--------|------------|--------------------------|
| NCT03907826 NPC  | Recurrent  | PD-1 antibody + Chemoradiotherapy (IMRT + GP)          | Chemoradiotherapy (IMRT + GP)                    | Phase 3| 212        | OS                       |
| NCT04907370 NPC  | Advanced   | Toripalimab (Anti-PD-1) + Induction Chemotherapy + IMRT | Toripalimab (Anti-PD-1) + Induction Chemotherapy + CCRT | Phase 3| 520        | FFS                      |
| NCT04557020 NPC  | Advanced   | PD-1 antibody + Chemotherapy + IMRT                    | Chemotherapy + IMRT                              | Phase 3| 200        | PFS                      |
| NCT03700476 NPC  | Advanced   | Sintilimab (Anti-PD-1) + Chemotherapy + IMRT          | Chemotherapy + IMRT                              | Phase 3| 425        | FFS                      |
| NCT05097209 NPC  | Advanced   | Camrelizumab (Anti-PD-1) + Chemotherapy + IMRT        | Chemotherapy + IMRT                              | Phase 3| 458        | PFS                      |
| NCT05340491 NPC  | Recurrent  | Chemotherapy + IMRT                                   | Chemotherapy + IMRT                              | Phase 3| 212        | OS                       |
| NCT04453826 NPC  | Recurrent  | Camrelizumab (Anti-PD-1) + Chemoradiotherapy arm       | Chemoradiotherapy alone                          | Phase 3| 388        | PFS                      |
| NCT04890522 NPC  | Metastatic | Triprilimab (Anti-PD-1) + Cisplatin + 5-Fluorouracil  | Triprilimab (Anti-PD-1) + Cisplatin + Gemcitabine | Phase 2| 622        | OS, FFS                  |
| NCT05342792 NPC  | (T4N+ or TanyN2-3M0) | PD-1 antibody + Metronomic Caeptitabine (Chemotherapy) | Metronomic Caeptitabine (Chemotherapy)            | Phase 3| 556        | FFS                      |
| NCT02611960 NPC  | (Recurrent/Metastatic) | Pembrolizumab (Anti-PD-1) | Capectabine + Gemcitabine + Docetaxel (Chemotherapy) | Phase 3| 233        | OS                       |

*BSC best supportive care, DFS disease-free survival, EFS event-free survival, ORR objective response rate, OS overall survival, PAEs percentage of participants with adverse events, PFS progression-free survival, RFS recurrence-free survival, TEAEs incidence of treatment-emergent adverse events, TIR time in response, TTP time to progression, SAER serious adverse event incidence rates, SBRT stereotactic body radiotherapy, 3D-CRT three-dimensional conformal radiation therapy, IMRT intensity-modulated radiation therapy, CCRT concurrent chemoradiotherapy*
experiments suffer from “drop out” events due to the randomness of gene expression and the failure of RNA capture or amplification during the sequencing process. It is necessary to use methods such as “Harmony,” “LIGER,” and “Seurat 3” to eliminate batch effects [269]. In addition, mining the informative single-cell transcriptomic and spatial transcriptomic data is a big challenge for researchers; new analysis tools such as artificial intelligence (AI) technology such as deep learning are needed. Nevertheless, we believe that reshaping the STIE and TIME in advanced solid tumors provides a promising approach to enhance efficacy of the immunotherapy. It is encouraging to note that there are a significant number of clinical trials of anti-PD-1/PD-L1 ongoing, with example lists of phase III–IV trials in lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma shown in Table 5. With all of these, plus collaborations among multidisciplinary investigators from clinical bedside to the basic benchside, and researchers crossing fields from computer science, biologist, dosimetrist, and physics, we will advance the field to a new horizon of success.

Abbreviations
3D-CRT: Three-dimensional conformal radiation therapy; ADC: Antibody-drug conjugate; AI: Artificial intelligence; BMT: Brain metastasis; CAF: Cancer-associated fibroblast; CC: Cancer cell; CRS: Cytokine release syndrome; CSC: Cancer stem cell; DC: Dendritic cell; EBV: Epstein–Barr virus; ECM: Extracellular matrix; EMT: Epithelial–mesenchymal transformation; ESC: Esophageal cancer; GDNF: Giall cell line-derived neurotrophic factor; GFRα3: GDNF family receptor alpha 3; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HPD: Haptoglobin; ICI: Immune checkpoint inhibitor; IDO: Indoleamine 2,3-dioxygenase; IFN-α: Interferon-α; irAEs: Immune-related adverse events; Kyn: Kynurenine; Mac: Macrophage; MAIN: Mutation-associated neoantigen; MDSC: Myeloid-derived suppressor cell; Msi: Microsatellite instability; NGS: Next-generation sequencing; NC: Nature killer cells; NLR: Neutrophil-to-lymphocyte ratio; NPC: Nasopharyngeal carcinoma; NSCLC: Non-small cell lung cancer; OS: Overall survival; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1; PFS: Progression-free survival; RCC: Renal cell carcinoma; RT: Radiation therapy; SBRT: Stereotactic body radiotherapy; scRNA-Seq: Single-cell RNA sequencing; Spd-L1: Soluble PD-L1; ST: Spatial transcriptomics; STIE: Systemic tumor immune environment; TAM: Tumor-associated macrophage; TEff: Effector T cells; Tex: Exhausted CD8+ T cells; Texp: Precursor exhausted CD8+ T cells; TGF-β1: Transforming growth factor-beta1; TIME: Tumor immune microenvironment; TLS: Tertiary lymphoid structure; TMB: Tumor mutation burden; TEM: Tumormicroenvironment; Treg: Regulatory T cell; Trp: Tryptophan; VEGF: Vascular endothelial growth factor; α-SMA: α-Smooth muscle actin.

Acknowledgements
We thank the group members from Xinyuan Guan, Yuzhu Hou, Chang Zou, and Feng-Ming (Spring) Kong for their assistance in grant application that conducts the idea of this review.

Author contributions
The concept of this paper was devised by FMK, XYG, YZH, and CZ. LLX wrote the main manuscript text. LLX and SSZ prepared Tables 1, 2, and 3. SSZ prepared Figs. 1, 2, 3, 4, 5, and 6. SWD prepared Fig. 7. TSC and BL made a key edit in the preliminary manuscript. All authors reviewed and approved the final manuscript.

Funding
This study was supported in parts by the Shenzhen Science and Technology Program (KQTD20180411185028796), National Natural Science Foundation of China (8187110989), and China Postdoctoral Science Foundation (2021M693291).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong 518053, China. 2 Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong 518020, China. 3 Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Shenzhen, Guangdong 518020, China. 4 Key Laboratory of Medical Electrophysiology of Education Ministry, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646100, China. 5 Department of Chemical Biology, School of Life and Marine Sciences, Shenzhen University, Shenzhen, Guangdong 518000, China. 6 Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK. 7 Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. 8 Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 9 Advanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 528200, China. 10 Chinese Academy of Sciences Shenzhen Institutes of Advanced Technology, Shenzhen, Guangdong 518055, China. 11 Guangdong Provincial Key Laboratory of Digestive Cancer Research, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China. 12 Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.

Received: 9 March 2022 Accepted: 22 June 2022
Published online: 07 July 2022

References
1. Kennedy LB, Salama AKS. A Review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.
2. Marin-Acevedo JA, Kibbrough EQ, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.
3. Akinleye A, Rasool Z. Immune checkpoint inhibitors of Pd-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.
4. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–22.
5. Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, et al. Use of immunotherapy with programmed cell death 1 versus programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375–84.
6. Wu W, Liu Y, Zeng S, Han Y, Shen H. Intra-tumor heterogeneity: the hidden barrier to immunotherapy against msi tumors from the perspective of ifn-β signaling and tumor-infiltrating lymphocytes. J Hematol Oncol. 2021;14(1):160.
7. Huang RSP, Haberberger J, Severson E, Duncan DL, Hemmerich A, Edgerly C, et al. A pan-cancer analysis of Pd-L1 immunohistochemistry
and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol. 2021;34(2):252–63.
8. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–56.
9. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase i keynote-001 study. J Clin Oncol. 2019;37(28):2518–27.
10. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
11. Kelley RK. Atezolizumab plus bevacizumab: a landmark in liver cancer. N Engl J Med. 2020;382(20):1953–5.
12. Finn RS, Qin S, Ikeda M, Galon J, Rizvi NA, Ahn M-J, et al. Immune checkpoint blockade: updated overall survival (OS) data from a global, randomized, open-label phase iii study of atezolizumab (ATZ) + bevacizumab (BVE) vs sunitinib (SUN) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267–267.
13. Kelley RK. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.
14. Xiao L, Kang W, Liao J, Li Y. Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis. Braz J Otorhinolaryngol. 2021.
15. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (Shr-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1388–50.
16. Liu S-Y, Wu Y-L. Ongoing clinical trials of Pd-1 and Pd-L1 inhibitors for lung cancer in China. J Hematol Oncol. 2017;10(1):136–136.
17. Luo X-Y, Wu K-M, He X-X. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res. 2021;40(1):172–172.
18. Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? Int J Cancer. 2020.
19. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the Ca209-003 study. J Clin Oncol. 2018;36(17):1675–84.
20. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Immunol. 2018;18(5):284–96.
21. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Restriction of Pd-1 function by Cis-Pd-L1/Cd80 interactions is required for optimal T cell responses. Science. 2019;364(6440):558–66.
22. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Sign Transduc Target Ther. 2020;5(1):99.
23. Wang H, Zhang H, Wang Y, Brown ZJ, Xia Y, Huang Z, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing. Adv Sci (Weinh). 2020;7(13):2000224.
24. Li G, Yuan L, Liu J, Zhao H. Comments on "Nafld causes selective Cd4+ T lymphocyte loss and promotes hepatocarcinogenesis* Hepatobiliary Surg Nutr. 2016;5:509–10.
25. Chen G, Zhang PG, Li SJ, Duan JJ, Su W, Guo SP, et al. Th1 cell frequency and II-17a production in peripheral blood of patients with non-small-cell lung cancer. J Int Med Res. 2020;48(6):300065202095498.
26. Kawai T, Etzold M, Jouppila P, Jani S, Linsley PS, et al. Dual targeting of Tgf-β and Pd-L1 via a bifunctional anti-Pd-L1/Tgf-βrii agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1).
27. Li G, Yuan L, Liu J, Zhao H. Comments on "Nafld causes selective Cd4+ T lymphocyte loss and promotes hepatocarcinogenesis* Hepatobiliary Surg Nutr. 2016;5:509–10.
28. Chen G, Zhang PG, Guo H, Zhou N, Fang Y, et al. T cells drive negative feedback mechanisms in cancer. Nat Rev Immunol. 2019;19(2):89–103.
29. Lin Y, Wang Y, Brown ZJ, Xia Y, Huang Z, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterol. 2017;153(4):1107-1119.e10.
30. Ye L, Zhang Q, Cheng Y, Chen X, Wang G, Shi M, et al. Tumor-derived exosomal Hmgb1 fosters hepatocellular carcinoma immune evasion by promoting Timp-1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6(1):145.
31. Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342-1356.e16.
32. Wang H, Zhang H, Wang Y, Brown ZJ, Xia Y, Huang Z, et al. Analysis of early stage nasopharyngeal carcinoma by single-cell cytometry and transcriptome sequencing. Adv Sci (Weinh). 2020;7(13):2000224.
33. Chen G, Sprenger D, Boor PPC, Doukas M, Schutt H, Mancham S, et al. Targeted therapies in advanced hepatocellular carcinoma. Gastroenterol. 2017;153(4):1107-1119.e10.
49. Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, et al. IL-6 promotes Pd-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type B expression in human hepatocellular carcinoma. J Immunother Cancer. 2020;8(1)

50. Ren Z, Yue Y, Zhang Y, Dong J, Liu Y, Yang X, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microspheres. Front Immunol. 2021;12:624789.

51. Elwan N, Salem ML, Kobotan A, El-Kalla F, Mansour L, Yousef M, et al. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cHCC-patients. Immunit Invest. 2018;47(2):169–80.

52. Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, et al. Ccl14 Is a Prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging. 2020;12(1):784–807.

53. Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. (2021) Liver Metastasis Restrains Immunotherapy Effect Via Macrophage-Mediated T Cell Elimination. Nat Med 27(1):152-164.

54. Yang W, Feng Y, Zhou J, Cheung Otto K-W, Cao J, Wang J, et al. A selective Hdcab inhibitory potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13(588):eaaz6804.

55. Wu F, Xu L, Tu Y, Cheung OKW, Szeto LLM, Mok MAT, et al. Sirtun 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Lett. 2021.

56. Liu Y, He S, Wang XL, Peng W, Chen QY, Chi DM, et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat Commun. 2021;12(1):741.

57. Zhao J, Guo C, Xiong F, Yu J, Ge J, Wang H, et al. Single cell ma-sequencing reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma. Cancer Lett. 2020;477:131–43.

58. Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30(11):1024–42.

59. He JR, Qin H, Ren ZF, Cui C, Zhang Y, Ranatunga D, et al. Mmp-9 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Clin Chem Lab Med. 2011;49(4):705–10.

60. Fliss-Jaber L, Houissa-Kastally R, Bouzouita K, Khediri N, Khelifa R. Elevated transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis: A systematic review and meta-analysis. 2021; 11(5186).

61. Liu L, Yao J, Ding Q, Cao R, Wang J, Huang S. Cxcr5(-) Cd4+Th-cXcl13 HighRegulatory cells in peripheral blood of nasopharyngeal carcinoma. Lin Chuang Er Bing Zhen 2017; 19(20):929–31.

62. He JR, Xi J, Ren ZF, Qin H, Zhang Y, Zeng YX, et al. Complement receptor 1 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2012;13(12):6527–31.

63. Qu Y, Wang D, Yang J, Liu HY, Cui W, Che YQ. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol. 2018;10(1):75–81.

64. Li JP, Wu C-Y, Chen M-Y, Liu S-Y, Yan S-M, Kang Y-F, et al. Pd-L1(+)Cxcr5(-) Cxcl13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer. 2021;9(7):e020101.

65. Liou AK, Soon G, Tan L, Peng Y, Cher BM, Goh BC, et al. Elevated IIL8 levels in nasopharyngeal carcinoma induced Pd-L1 expression on NK cells in its leading to poor prognosis. Oral Oncol. 2020;104:104616.

66. Ménetrier-Caux C, Ray-Coquard I, Blay J-Y, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 2019;7(1):85–85.

67. Kong FM, Zhao J, Wang J, Li S, Finard M. Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis. 2014;6(4):336–47.

68. Bao J, Lin J, Long J, Yang X, Yang X, Lu X, et al. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. Am J Cancer Res. 2020;10(12):4585–606.
90. Wang W, Huang L, Jin JY, Jolly S, Zang Y, Wu H, et al. Ido immune status after chemoradiation may predict survival in lung cancer patients. Cancer Res. 2018;78(3):809–16.

91. Wang W, Huang L, Jin JY, Pi W, Ellsworth SG, Jolly S, et al. A validation study on ido immune biomarkers for survival prediction in non-small cell lung cancer: radiation dose fractionation effect in early-stage disease. Clin Cancer Res. 2020;26(1):282–9.

92. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting Cta-4. J Exp Med. 2013;210(7):1389–402.

93. Meireiros A, Devos M, Brochez L. Ido expression in cancer: different compartment, different functionality? Front Immunol. 2020;11:531491.

94. Zhai L, Dey M, Lauring KL, Gritsina G, Kaur R, Lukas RV, et al. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci. 2015;22(12):1964–8.

95. Mulligan LM. Ret revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14(3):173–86.

96. Banerjee A, Qian P, Wu ZS, Ren X, Steiner M, Bougen NM, et al. Artemin stimulates radio- and chemo-resistance by promoting twist1-Bcl-2-dependent cancer stem cell behavior in mammary carcinoma cells. J Biol Chem. 2012;287(51):42502–15.

97. Causig IN, Zhao J, JZ, Vaghasia A, Zhang B, Hisue EH-C, et al. Transcriptional programs of neoantigen-specific T cells in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126–32.

98. Zhang Y, Dai W, Xu L, Ma L, Liang Z, Zhao C, et al. P21.01 selected ctDNA panel gene sequencing for neoantigen discovery and survival prediction in patients with stage IV non-small cell lung cancer. J Thorac Oncol. 2021;16(10):S1023.

99. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunology. 2013;39(1):110–1.
Adashek, J.J., Subbiah, I.M., Maito, I., Garralda, E., Mehta, A.K., Ganeshan, D.M., et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer. 2020;6(3):181–91.

Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., et al. Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to Pd-1/Pd-L1 blockade. Clin Cancer Res. 2019;25(3):989–99.

Kato, S., Goodman, A., Walavalkar, V., Barkauskas, D.A., Sharabi, A., Kurzrock, R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–50.

Xiong, D., Wang, Y., Singavgi, A.K., Mackinnon, D., Xu, X., Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., et al. Immuno-therapy for patients with stage II lung cancer. Thorac Cancer. 2020;11(11):3194–44.

Rodriguez-Ruiz ME, Vanpouille-Box C, Melero I, Forcinti S, Demaria S. Immunological mechanisms responsible for radiation-induced abscessal effect. Trends Immunol. 2018;39(8):644–55.

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A.B., et al. Consensus guidelines for the definition, detection and interpretation of immunomigrative cell death. J Immunother Cancer. 2020;8(1).

Neophytou CM, Pierides C, Christodoulou M, Costeas P, Kyriakou TC, Papageorgis P. The role of tumor-associated myeloid cells in modulating immune therapy. Front Oncol. 2020;10:899.

Dorsey, J.F., Kao, G.D., MacArthur, K.M., Ju, M., Steinmetz, D., Wileyro, E.P., et al. Tracking viable circulating tumor cells (Ctcs) in the peripheral blood of non-small cell lung cancer (Nscic) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015;121(1):139–49.

Wang, Q., Li, S., Qiao, S., Zheng, Z., Duan, X., Zhu, X. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol. 2017;8:468652.

Lei, Q.Q., Sui, J.D., Jin, F., Luo, H., Shan, J., Tang, L., et al. Impact of high-dose rate radiotherapy on B and natural killer (NK) cell polarization in peripheral blood mononuclear cells (Pbmc) via inducing non-small cell lung cancer (Nscic)-derived exosomes. Trans Cancer Res. 2021;10(7):3538–47.

Punjabi, A., Barrett, E., Cheng, A., Mulla, A., Walls, G., Johnston, D., et al. Neutrophil-lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small cell lung cancer. Clin Oncol (R Coll Radiol). 2021;33(8):e381–8.

Siva, S., Lebochovsky, P., MacManus, M.P., Cron, T., Moller, A., Lob, R.J., et al. Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues. Clin Cancer Res. 2022;16(19):4817–26.

Chen, J., Cao, Y., Markelc, B., Kaeple, J., Veerm, J.A., Muschel, R.J. Ty I Ifn protects cancer cells from Cdb+ cell-mediated cytotoxicity after radiation. J Clin Invest. 2019;129(10):4224–38.

Wong, H.H., Yeo, W., Leung, T., Lau, W.W., Johnson, P.J. Circulating tumor cell mamas in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett. 2001;167(2):183–91.

Xiang, Z.L., Zeng, Z.C., Fan, J., Tang, Z.Y., He, J., Zeng, H.Y., et al. The expression of Hif-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep. 2012;39(2):2101–9.

Kim, H.J., Park, S., Kim, K.J., Seong, J. Clinical significance of soluble programmed cell death ligand-1 (Spd-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol. 2018;129(1):130–5.

Pichler, C., Weber, J., Smith, C., van der Meulen, A., Hall, J., et al. Divergent association between circulating lymphocyte populations with outcome after radiation therapy in subtypes of liver cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1222–5.

Li, T.T., Sun, J., Wang, Q., Li, W.G., He, W.P., Yang, R.C., et al. The effects of stereotactic body radiotherapy on peripheral natural killer and Cdb3(+) Cdb5(+) Nkt-like cells in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2021;20(3):240–50.

Zhu, C., Jiang, X., Xiao, H., Guan, J. Tumor-derived extracellular vesicles inhibit Hgf/C-Met and Egfr pathways to accelerate the radiosensitivity of nasopharyngeal carcinoma cells via microrna-142-5p delivery. Cell Death Discov. 2022;8(1):17.

Hui, E.P., Ma, B.B.Y., Lam, W.K.Y., Chan, K.C.A., Mo, E.A., Qi, H., et al. Dynamic changes of post-radiotherapy plasma Epstein-Barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer. Clin Cancer Res. 2021;27(10):2827–36.

Li, H., Chen, X., Zeng, W., Zhou, W., Zhou, Q., Wang, Z., et al. Radiation-enhanced expression of Cdd2 in nasopharyngeal carcinoma is associated with Cdd4(+)/Cdb T cell recruitment. Int J Radiat Oncol Biol Phys. 2020;108(1):126–39.

Yu, Y., Qian, L., Cui. J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol. 2017;7(3):498–506.
176. Maehata Y, Onishi H, Kuniyama K, Aoki S, Araya M, Saito R, et al. Immune responses following stereotactic body radiotherapy for stage i primary lung cancer. Biomed Res Int 2013;2013:731346.

177. Weinshar N, Wu J, Meng Y, Madi A, Hotz-Wagenblatt A, Ma S, et al. Rgs16 promotes antitumor Cdh8(+) T cell exhaustion. Sci Immunol. 2022;7(71):eabf1873.

178. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted Cdh8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52(5):825-841 e8.

179. Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-Pd-1 therapy in lung cancer. Nat Cancer. 2022;5(1):108–21.

180. Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by Pd-1 blockade. Science. 2016;354(6316):1160–5.

181. Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. Tox is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–4.

182. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted Cdh8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7.

183. Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. Tox is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–4.

184. Seo H, Chen J, Gonzalez-Avalos E, Marconcini D, Das A, Wang YH, et al. Tox and Tox2 transcription factors cooperate with Nlr4 transcription factors to impose Cdh8(+) T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410–5.

185. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. Pd-L1 Mra expression in plasma-derived exosomes is associated with response to anti-Pd-1 antibodies in melanoma and Nsclc. Br J Cancer. 2018;118(6):820–4.

186. Pfister D, Núñez NG, Pasiqijn G, Reff E, Eivivald C, Blossie F, et al. Pd-L1 Mra expression in plasma-derived exosomes is associated with response to anti-Pd-1 antibodies in melanoma and Nsclc. Br J Cancer. 2018;118(6):820–4.

187. Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9(7).

188. Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Blossie F, et al. Pd-L1 Mra expression in plasma-derived exosomes is associated with response to anti-Pd-1 antibodies in melanoma and Nsclc. Br J Cancer. 2018;118(6):820–4.

189. Balança CC, Salvioni A, Scarlata CM, Michelas M, Martinez-Gomez C, Gomez-Roca C, et al. Pd-1 blockade restores helper activity of tumor-specific T cells in patients with primary hepatocellular carcinoma. Oncoimmunology. 2021;10(1):2002068.

190. Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antitumor response in patients treated with single-agent Pd-1/Pd-L1 inhibitors or platinum-based chemotherapy. J Clin Oncol. 2019;37(11):915–23.

191. Smith MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic Nsclc. Nat Rev Clin Oncol. 2017;14(8):414–27.

192. Wang X, Huang H, Song Q, Zuo J, et al. Pd-L1 Mrna expression in plasma-derived exosomes is associated with response to anti-Pd-1 antibodies in melanoma and Nsclc. Br J Cancer. 2018;118(6):820–4.

193. Chuah S, Lee J, Song Y, Kim HD, Water M, Kaya NA, et al. Uncoupling immune trajectories of response and adverse events from anti-Pd-1 immunotherapy in hepatocellular carcinoma. J Hepatol. 2022;

194. Schmidt NW, Wing PAC, Diniz MO, Pallet LJ, Swadling L, Harris JM, et al. Targeting human acyl-coa: cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. Nat Commun. 2021;12(1):2814.

195. Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets Fgf receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in Hcc. Hepatology. 2021;74(5):2544–60.

196. Smith MJ, Mcgrath J, Neller MA, Matthews KK, Koos K, Pesel T, et al. Complete response to Pd-1 blockade following Ebv-specific T-cell therapy in metastatic nasopharyngeal carcinoma. N Engl J Med. 2021;384(1):25–37.

197. Iwase T, Taniguchi M, Okazaki T, et al. Interferon-α sensitizes with radiotherapy to delay tumor growth by reversing T cell exhaustion in patients with advanced non-small cell lung cancer treated with single-agent Pd-1/Pd-L1 inhibitors or platinum-based chemotherapy. J Clin Oncol. 2021;39(2):149–57.

198. Makowska A, Braunschweig T, Denecke B, Shen L, Baloch V, Busson P, et al. Complete response to Pd-1/Pd-L1 checkpoint blockade in patients with advanced non-small cell lung cancer treated with single-agent Pd-1/Pd-L1 inhibitors or platinum-based chemotherapy. J Clin Oncol. 2021;39(2):149–57.

199. Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Baloche V, et al. Overcoming microenvironmental resistance to Pd-1 blockade in genetically engineered lung cancer models. Sci Transl Med. 2021;13(606).

200. Rizvi NA, Hellmann MD, Snyder A, Makarov V, Havel MJ, et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent Pd-1/Pd-L1 inhibitors or platinum-based chemotherapy. J Clin Oncol. 2021;39(2):149–57.
Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-Pd-1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1085–97.

218. Wang F, Luo L, Tian X, Ma S, Sun Y; You C, et al. Impact of radiotherapy concurrent with anti-Pd-1 therapy on the lung tissue of tumor-bearing mice. Radiat Res. 2019;191(3):271–7.

219. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8(25):41242–5.

220. Qin S, Xu L, Li M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and Ota-4. Mol Cancer. 2019;18(1):155.

221. Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, et al. Dual inhibition of Tgf-β and Pd-L1: a novel approach to cancer treatment. Mol Oncol. 2022;16(11):2117–34.

222. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Dual inhibition of Tgf-β signaling by antioxidants stimulates lung cancer metastasis. Cell. 2012;148(2):330–45.e22.

223. Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al. Tnfα blockade overcomes resistance to Anti-Pd-1 in experimental melanoma. Nat Commun. 2017;8(1):2256.

224. Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Impact of the antiangiogenic effect of Pd-1/Pd-L1 blockade via combination therapy and Pd-L1 regulation. J Hematol Oncol. 2022;15(1):24.

225. Amrein MA, Bühler ED, Amrein ML, Li Q, Rothchild S, Riether C, et al. Chemotherapy negatively impacts the tumor microenvironment in Nsclc: an analysis of pre- and post-treatment biopsies in the multi-center Sakk19/09 study. Cancer Immunol Immunother. 2020;70(2):405–15.

226. Aldarouish M, Su X, Qiao J, Gao C, Chen Y, Dai A, et al. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer. Int J Immunopathol Pharmacol. 2019;33:2058738419839592.

227. Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Müller AJ. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol. 2018;336:175–203.

228. Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, et al. Impact of Egfr-Tki treatment on the tumor immune microenvironment in nasopharyngeal carcinoma proliferation and chemosensitivity through a Foxo1-modulated positive feedback loop with Mtor-P-Pi3k/Akt-C-Jun. Nat Commun. 2016;7:13190–41.
Pd-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–8.

259. Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, et al. Patients with short Pfs to Egfr-kiis predicted better response to subsequent anti-Pd-1/Pd-L1 based immunotherapy in Egfr common mutation Nsclc. Front Oncol. 2021;11(424):639947.

260. Hui Z, Zhang J, Xiao S, Pu Y, Lin R, Wang T, et al. Comprehensive immune cell analysis from lung cancer patients with Pd-1 inhibitor neoadjuvant immunotherapy using single cell sequencing. J Clin Oncol. 2020;38(15_suppl):e21001–e21001.

261. Clarke J, Panwar B, Madrigal A, Singh D, Gujar R, Wood G, et al. Single-cell transcriptomic analysis of tissue-resident Memory T cells in human lung cancer. J Exp Med. 2019;216(9):2128–49.

262. Zhang F, Bai H, Gao R, Fei K, Duan J, Zhang Z, et al. Dynamics of peripheral T cell clones during Pd-1 blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2020;69(12):2599–611.

263. Kim K, Park S, Park SY, Cho JW, et al. Single-Cell Transcriptome Analysis Reveals Tox as a Promoting Factor for T Cell Exhaustion and a Predictor for Anti-Pd-1 Responses in Human Cancer. Genome Med. 2020;12(1):22.

264. Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, Wang XW. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. J Hepatol. 2021;74(3):700–15.

265. Zhang L, Mao S, Yao M, Chao N, Yang Y, Ni Y, et al. Spatial transcriptome sequencing revealed spatial trajectory in the non-small cell lung carcinoma. 2021: 2021.04.26.441394.

266. Wu R, Guo W, Qiu X, Wang S, Sui C, Liu Q, et al. Comprehensive analysis of spatial architecture in primary liver cancer. 2021: 2021.05.24.445446.

267. Mai HQ, Chen QT, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536–43.

268. Makowska A, Lelabi N, Nothaum C, Chen L, Busson P, Tran TTB, et al. Radiotherapy combined with Pd-1 inhibition increases Nk cell cytotoxicity towards nasopharyngeal carcinoma cells. Cells. 2021, 10(9).

269. Tran HTN, Ang KS, Chevrier M, Zhang X, Lee-NyS, Goh M, et al. A benchmark of batch-effect correction methods for single-cell rna sequencing data. Genome Biol. 2020;21(1):12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.